

Index

- abdominal and extra-abdominal
 desmoid tumors *see*
 fibromatosis
- abscess
 amoebic 466
 liver 466
 lung 422–3
 pyogenic, liver 466
 renal 573–4
 subareolar 346–7, 350, 368
- acinar cell carcinoma
 pancreas 496–7
 pancreatic endocrine
 neoplasm *vs.* 497
 pancreatoblastoma *vs.* 496
 solid-pseudopapillary
 neoplasm of pancreas
vs. 495
- acinic cell carcinoma
 mammary analog secretory
 carcinoma *vs.* 326
 MASC *vs.* 326
 oncocytoma *vs.* 319
 salivary glands 324–5
 sialadenosis *vs.* 325
- acquired cystic kidney (ACK)-
 associated renal cell
 carcinoma (RCC) 550
- actin 372
- Actinomyces*
 in Pap smear 9
 in respiratory infections 55
- acute lymphadenitis 396–7
- acute pancreatitis 485–6
- acute sialadenitis 307–8
- acute suppurative thyroiditis,
 granulomatous (de
 Quervain's) thyroiditis
vs. 257
- acute thyroiditis 256–7
- adenocarcinoma (ADC)
 bladder neoplasms 174–5
 body cavity fluids 99–100
 breast 25–6
 signet ring 351
 bronchogenic
 ADC-LP/AIS 68–9
 invasive 65–8
 colonic 26–7, 108, 479
- cytomorphology
 high grade columnar/ductal
 624–5
 low grade columnar/ductal
 624
- differential diagnosis
 adrenal cortical carcinoma
 583–5
 autoimmune pancreatitis 487
 carcinoid tumor 142
 chemotherapy-associated
 atypia 138
 chordoma 539
 chronic pancreatitis 487
 gastric adenocarcinoma 144
 gastric dysplasia 140
 gastric xanthoma 140
 inflammatory bowel disease
 150
 large cell undifferentiated
 carcinoma of lung 431
 lymphoma 144
 mesothelioma 440
 metaplastic carcinoma 368
 peptic ulcer disease 137
 squamous cell carcinoma
 131, 428
 villous adenoma 146
- duodenum 146
- endocervical 21–2
 in situ 18–19, 21
- endometrial 22–3
- endometrioid 105–6
- esophagus 131–3
- Fallopian tube 24–5
- gastric 26, 107–8, 138–40
 diffuse form 144
- large intestine 150–2
- lung 99–100, 427–8
 poorly differentiated 430
- metastatic 428, 440
- ovarian
 metastatic 24–5
 mucinous 104–5
 papillary serous 24
- pancreas 109–10
 ductal 492–4
 mucinous 492
 well differentiated 492
- Pap smear
 breast 25–6
 colon 26–7
 endocervical 21–2
 endometrial 22–3
 gastric 26
 in-situ of endocervix 21
 prostate 172
 salivary gland 317, 327–8
 stomach 138–40
 of unknown origin 621, 624
- adenocarcinoma-in-situ (AIS) of
 endocervix 18–19, 21
- adenoid cystic carcinoma
 breast, collagenous spherulosis
vs. 351
 salivary glands 322–4
 benign mixed tumor/
 pleomorphic adenoma
vs. 315
 epithelial-myoepithelial
 carcinoma *vs.* 328
 polymorphous low grade
 adenocarcinoma *vs.* 328
- adenoma
 adrenal cortical 583–6
 basal cell adenoma, salivary
 glands 316–18
 bile duct 470–1
 breast
 lactational 348
 tubular 352–3
 differential diagnosis, bladder
 adenocarcinoma 174
 hepatocellular 470
 large intestine 150–2
 parathyroid 283–4
 thymic neuroendocrine
 carcinoma *vs.* 447
 pleomorphic adenoma 313–16
 salivary gland 313–16
 basal cell 316–18, 323
 carcinoma ex-pleomorphic
 329–30
 monomorphic 316
- adenomatoid nodule, thyroid
 252–5
- adenomatoid tumor 610–11
- adenomatous hyperplasia 471–2
- adenosis, breast
 microglandular 351
 sclerosing 352
- adenovirus 167
- adequacy
 Pap smear 1–2
 thyroid fine needle aspiration
 252
- adrenal cortical adenoma and
 hyperplasia 583–6
- adrenal gland tumors 583–9
 adrenal cortical adenoma and
 hyperplasia 583–6
 metastases, clinical patterns
 of 637
 metastatic 587
 myelolipoma 589
 neuroblastic 588–9
 pheochromocytoma 586–7
 adrenal cortical carcinoma
vs. 584, 586
 melanoma *vs.* 586
 metastatic carcinoma *vs.*
 586
- adrenocortical carcinoma (ACC)
 585–6
 clear cell renal cell carcinoma
vs. 557
 cortical adenoma/hyperplasia
vs. 584
 metastatic adenocarcinoma
vs. 585
 pheochromocytoma *vs.* 586
 prostatic adenocarcinoma *vs.*
 584
 renal cell carcinoma *vs.* 585
 sarcomatoid renal cell
 carcinoma *vs.* 566
- AE1/AE3 112, 187, 274, 444, 473
- Alcian blue 189, 439
- ALK 63, 261, 378, 410, 415, 427,
 457
- α-fetoprotein 113, 472, 637
- Alternaria alternata*, in Pap
 smear 11
- alveolar lining cells
 type I pneumocytes 43
 type II pneumocytes 43
 hyperplasia 43–5

Index

- alveolar rhabdomyosarcoma 535–7
 alveolar soft part sarcoma *vs.* 514
 alveolar soft part sarcoma 513–14
 extrarenal rhabdoid tumor *vs.* 517
 granular cell tumor *vs.* 513
 alveolar spaces, cells within 45–6
 amelanotic melanoma, breast lymphoma *vs.* 378
 American Society of Colposcopy and Cervical Pathology (ASCCP) 2
 amiodarone lung 60
 amoebic abscesses 466
 amyloid 498
 amyloid goiter 259
 amyloidosis
 liver 468
 pulmonary 74–5
 anal Pap smear 29–30
 anaplastic astrocytoma 219–21
 anaplastic large cell lymphoma 410–11
 Hodgkin's lymphoma *vs.* 404, 450
 mediastinal seminoma *vs.* 452
 anaplastic (undifferentiated) thyroid carcinoma (UTC) 273–4
 medullary thyroid carcinoma *vs.* 272
 ancillary studies, salivary glands 305
 aneurysmal bone cyst
 chondroblastoma *vs.* 533
 giant cell tumor of bone *vs.* 531
 angiomyolipoma (AML) 572–3
 clear cell RCC *vs.* 557, 572
 hemangioma *vs.* 469
 liposarcoma *vs.* 572
 sarcomatoid RCC *vs.* 565, 572
 angiosarcoma
 hemangioma *vs.* 542
 liver 476–7
 melanoma *vs.* 542
 soft tissue and bone 541–2
 antimitochondria antibody 319
 anus 152–4
 squamous dysplasia and HPV 152–4
 apocrine carcinoma of breast 369–70
 arginase 1 634
 Arias-Stella change of pregnancy 3–4
 arteriovenous malformation (AVM), central nervous system 215
 Aspergillus spp. 60
 aspiration pneumonia 54
 asteroid hyalosis 189
 atheroscleroids, in Pap smear 11–12
 astrocytic neoplasms 223–5
 anaplastic 219–21
 gliosarcoma 224–5
 low-grade 218–19
 pilocytic astrocytoma 223–4
 small cell glioblastoma multiforme 224
 asymptomatic parotid hypertrophy 305–6
 atypia
 chemotherapy-associated 138
 proliferative breast disease without/with 355–6
 thyroid, of undetermined significance 260–2
 atypical carcinoid, neuroendocrine 69–71
 atypical squamous cells (ASC) cannot exclude high grade squamous intraepithelial lesion (ASC-H) 14–15
 of undetermined significance 14, 159
 atypical teratoid/rhabdoid tumors (AT/RT) 229–30
 autoimmune pancreatitis 487–8
 B-cell lymphoblastic lymphomas 409–10
 B-cell lymphoma
 diffuse large 408–9
 primary mediastinal large 447–8
 Bacillus Calmette–Guerin (BCG) granulomas 170
 bacterial endophthalmitis 190–1
 bacterial infections
 effusions 89
 urinary tract 169
see also specific bacterial infections
 bacterial meningitis 180–1, 206–7
 bacterial pneumonia 55
 bacterial vaginosis 4
 barbotage 166
 Barrett's esophagus 127–9
 dysplasia in 129–30
 GERD *vs.* 127
 basal cell adenoma, salivary glands 316–18
 basal cell carcinoma
 Merkel cell carcinoma *vs.* 293
 pilomatixoma *vs.* 295
 basaloid adenoma 316–18
 basaloid squamous cell carcinoma
 large cell neuroendocrine carcinoma *vs.* 433
 small cell carcinoma *vs.* 433
 BCG vaccine, urine changes 170
 bcl-2 378, 415, 441
 bcl-6 378, 416
 benign body cavity fluids 83
 benign cystic lesions
 central nervous system 215–17
 colloid cyst of the third ventricle 217
 craniopharyngoma 215–16
 epidermoid cyst 216–17
 Rathke's cleft cyst 216
 benign diseases, central nervous system (CNS) 204–5
 cerebrospinal fluid findings, normal 204–5
 benign findings, in Pap smear 2–13
 Arias–Stella change of pregnancy 3–4
 endometrial cells 2–3
 relative changes associated with inflammation 4–6
 benign follicular nodules, thyroid gland 252–9
 acute thyroiditis 256–7
 adenomatoid nodule 252–5
 amyloid goiter 259
 chronic lymphocytic (Hashimoto's) thyroiditis 255–6
 colloid nodule 252–5
 granulomatous (subacute or de Quervain's) thyroiditis 257–8
 Graves' disease 258–9
 hyperplastic nodule 252–5
 Riedel's thyroiditis 258
 benign intraparotid lymph node 312
 benign lymphoepithelial cyst (cystic BLL) 309–11
 Warthin's tumor *vs.* 321
 benign lymphoepithelial lesions (BLL) 311–12
 benign mesenchymal tumor, sarcoma *vs.* 377
 benign mixed tumor/
 pleomorphic adenoma 313–16
 benign mixed tumor, salivary glands 313–16
 benign neoplasms, salivary glands 313–21
 basal cell adenoma 316–18
 benign mixed tumor/
 pleomorphic adenoma 313–16
 myoepithelioma 318
 oncocytoma 319–20
 Warthin's tumor 320–1
 benign neoplastic hepatic lesions 468–71
 bile duct adenoma/hamartoma 470–1
 focal nodular hyperplasia 469–70
 hemangioma 468–9
 hepatocellular adenoma 470
 benign nonneoplastic hepatic lesions 464–5
 congenital ciliated hepatic foregut cyst 464–5
 simple cysts 464
 benign peripheral nerve sheath tumor 453–4
 ganglioneuroma *vs.* 456
 MPNST *vs.* 455
 Ber-EP4 95, 103, 104, 110, 442
 beta-catenin 363, 373, 495
 Bethesda System 251–2
 BG-8 95, 439, 442
 bile duct adenoma/hamartoma 470–1
 bile duct carcinoma (cholangiocarcinoma) 110, 474–5
 hepatocellular carcinoma *vs.* 473
 mixed hepatocellular/cholangiocarcinoma 473
 bile duct epithelial cells 464
 bile duct hamartoma (adenoma) 470–1
 bile pigments 464
 biopsy
 central nervous system tumors 241–2
 fine needle (*see* fine-needle aspiration (FNA))
 stereotactic needle biopsy 202
 Birbeck's granules 518
 bladder neoplasms 174–5
 adenocarcinoma 174–5
 lymphoma 178
 secondary malignancies 175
 small cell carcinoma 175
 squamous cell carcinoma 174
 urothelial carcinoma 27–8, 115–16, 170–4
 bladder washing/barbotage 166
 blastoma, hamartoma *vs.* 425
 blastomycosis 56
 “blue blobs” 5
 body cavity fluids 82–116
 benign/reactive 83
 effusions, types of 83–92
 associated with SLE 88–9
 bacterial infections 89
 cirrhosis 90–1
 detached ciliary tufts 86–7
 eosinophilic effusions 87
 exudate fluids 83
 fungal/parasitic infections 90
 hematopoietic cells 86
 infarction 92
 macrophages 86
 mesothelial cells, from normal to reactive 83–6
 pancreatitis 91–2
 rheumatoid pleuritis 88
 transudate fluids 83
 tuberculous effusions 89
 uremia 91
 viral infections 89–90
 gastric adenocarcinoma 107–10
 bile duct (cholangiocarcinoma) 110

- colonic adenocarcinoma 108
- hepatocellular carcinoma 110
- pancreatic adenocarcinoma 109–10
- pseudomyxoma peritonei 110
- gastrointestinal tumors 106–7
- esophageal carcinoma 107
- hematopoietic neoplasms (lymphoma and leukemia) 110–12
- primary effusion lymphoma 111–12
- international system for serous effusions cytopathology 82–3
- malignant mesothelioma 92–7
- malignant tumors, miscellaneous 112–16
- germ cell tumors 112–14
- melanoma 115
- renal cell carcinoma 115
- sarcoma 112
- urothelial cell carcinoma 115–16
- Wilms tumor (nephroblastoma) 116
- metastatic carcinoma 97–103
- adenocarcinoma 99–100
- breast carcinoma 97–9
- lung carcinoma 99
- small cell carcinoma 102–3
- squamous cell carcinoma 101–2
- tumors of Mullerian origin 103–6
- cervical carcinoma 106
- endometroid adenocarcinoma 105–6
- MADC 104–5
- MMMT (carcinosarcoma) 106
- ovarian borderline serous papillary tumor 104
- ovarian carcinoma 103–4
- uterine carcinoma 105
- see also individual tumors*
- bone cyst, aneurysmal chondroblastoma vs. 533
- giant cell tumor of bone vs. 532
- bone, fine-needle aspiration *see* soft tissue and bone tumors
- bone metastases, clinical patterns of
- large bones 636
- small bones 639–40
- branchial cleft cyst 285–7
- cystic squamous cell carcinoma vs. 289
- thyroglossal duct cyst vs. 287
- breast adenocarcinoma 25–6
- metaplastic carcinoma vs. 368
- signet ring 351
- breast adenoma lactational, fat necrosis vs. 348
- tubular 352–3
- tubular carcinoma vs. 364
- breast carcinoma adenoid cystic 350
- apocrine 369–70
- body cavity fluids 97–9
- ductal 360–3
- in-situ 358–9
- infiltrating 360–3
- squamous cell carcinoma vs. 368
- effusions 97–9
- lobular infiltrating 363
- lobular neoplasia vs. 360
- medullary 366–7
- metaplastic 367–8
- fibromatosis vs. 373
- phyllodes tumor vs. 372
- metastatic 25–6, 239, 481
- mucinous (colloid) 365–6
- phyllodes tumor vs. 372
- papillary ductal mucinous (colloid) carcinoma vs. 366
- papillary lesions vs. 358
- primary, no special type 360–3
- primary, special types 363–70
- proliferative breast disease vs. 356
- secretory 351, 354
- pregnancy changes vs. 354
- signet ring 351
- small cell 379
- lymphoma vs. 379
- spindle cell 375
- tubular 363–5
- tubular adenoma vs. 364
- breast cytopathology 340–83
- amelanotic melanoma, lymphoma vs. 378–9
- apocrine lesions 376
- ductal lavage 341–2
- fat necrosis 347–8, 351
- fibroadenoma myofibroblastoma vs. 375
- papillary lesions vs. 358
- phyllodes tumor vs. 372
- pregnancy changes vs. 354
- proliferative breast disease vs. 356
- tubular adenoma vs. 353
- tubular carcinoma vs. 364
- fibrocystic change 351
- fibroepithelial tumors 370–3
- benign 373
- fibroadenoma 370–1
- Phyllodes tumor 371–3
- sclerosing adenosis vs. 352
- fibromatosis 368, 373
- metaplastic carcinoma vs. 368
- myofibroblastoma vs. 375
- fine-needle aspiration 340–1
- galactocele, pregnancy changes vs. 354
- granular cell tumor 375–7
- malignant mesenchymal tumors (sarcomas) 376–7
- in-situ lesions of the breast 358–60
- ductal carcinoma in situ 358–9
- lobular neoplasia 360
- inflammatory breast lesions 345–9
- fat necrosis 347–8
- mastitis 345–6
- silicone-related changes 348–9
- subareolar abscess 346–7
- intraductal hyperplasia, papillary lesions vs. 358
- intramammary lymph node 378
- lobular neoplasia 360
- infiltrating ductal carcinoma vs. 363
- lymphomas 377–9
- male breast 380–2
- cancer 381
- gynecomastia 381
- metastatic tumors 381
- mastitis 345–6
- lymphoma vs. 378
- medullary carcinoma 366–7
- lymphoma vs. 379
- mesenchymal tumors 373–5
- fibromatosis 373
- granular cell tumor 376–7
- lipoma 374
- myofibroblastoma 374–5
- spindle cell lipoma 374
- metastases, clinical patterns of 638
- metastatic tumors 379–80
- mucocele-like lesions, mucinous (colloid) carcinoma vs. 365–6
- nipple discharge 342
- nodular fasciitis, myofibroblastoma vs. 375
- nonproliferative breast disease 349–55
- collagenous spherulosis 350–1
- cysts 349–50
- microglandular adenosis 351
- pregnancy and lactational changes 353–4
- sclerosing adenosis 352
- treatment induced changes 354–5
- tubular adenoma 352–3
- normal 342–5
- apocrine cells 343
- ductal cells 342
- foam cells 343
- myoepithelial cells 343
- papillary lesions 356–8
- nonproliferative breast disease vs. 350
- papillary ductal carcinoma 358, 366
- phyllodes tumor vs. 372
- proliferative breast disease vs. 356
- papilloma 356–8
- phyllodes tumor 371–3, 375
- fibroadenoma vs. 372
- metaplastic carcinoma vs. 368, 372
- myofibroblastoma vs. 375
- pregnancy/lactational changes 353–4
- infiltrating ductal carcinoma vs. 363
- prognostic/predictive factors in breast cytology 382–3
- proliferative breast disease without/with atypia 355–6
- fibroadenoma vs. 356
- infiltrating ductal carcinoma vs. 363
- tubular carcinoma vs. 364
- radial sclerosing lesions, tubular carcinoma vs. 364
- reactive lymphoid proliferation 378
- sarcoma 376–7
- fibromatosis vs. 373
- metaplastic carcinoma vs. 368
- schwannoma, myofibroblastoma vs. 375
- silicone-related changes 348–9
- specimen types in breast cytopathology 340–2
- ductal lavage 341–2
- fine needle aspiration biopsy of the breast 340–1
- nipple discharge cytology 342
- spindle cell tumor, myofibroblastoma vs. 375
- subareolar abscess 346–7
- breast cyst vs. 350
- metaplastic carcinoma vs. 368
- squamous cell carcinoma vs. 368
- Brenner tumor 603–4
- bronchial alveolar lavage (BAL) 38
- bronchial cell changes, reactive and reparative 40–1
- bronchial cell hyperplasia (Creola bodies) 42–3

Index

- bronchogenic adenocarcinoma
 invasive 65–8
 with lepidic predominant
 growth pattern 68–9
- bronchoscopic specimens (brush,
 wash, and lavage), in
 exfoliative respiratory
 cytology 38
- Brunner's glands 68–9
 hamartoma, neuroendocrine
 tumor vs. 147
 heterotopia, neuroendocrine
 tumor vs. 141
 hyperplasia, neuroendocrine
 tumor vs. 147
- B72.3 67, 72, 96, 442, 494, 496
- Burkitt lymphoma 411–12
- c-kit 20, 320, 323, 372, 433, 450,
 611, 612, 613
- CA IX 26, 499
- CA19-9 96
- CA125 103, 105
- calcifying epithelioma
 of Malherbe
 (pilomatrixoma) 295–6
- calcitonin 634
- calcospherites/psammoma
 bodies 49
- calponin 315, 318, 319, 356, 358,
 364
- calretinin 94, 96, 103, 104–9,
 439, 584, 587, 608, 610,
 629, 634
- CAM5.2 133, 557, 579
- Candida*
 esophagitis 123–4
 in Pap smear 6
 in respiratory infections 55
- Candida albicans* 6
- Candida esophagitis* 123–4
- “cannon-ball” cells 8
- carbon-laden histiocytes (dust
 cells) 46
- carcinoembryonic antigen *see*
 CEA
- carcinoid lung 426–7
- carcinoid tumor
 duodenum 145, 146, 147, 149
 gastric 145–9
 lymphoma vs. 147, 148
 lung 69–71, 426–7
 large cell neuroendocrine
 carcinoma vs. 433–4
 small cell carcinoma vs. 433
- spindle cell 437
- thymus 443
- carcinoma
 breast
 apocrine carcinoma
 369–70
 body cavity fluids 97–9
 infiltrating ductal 360–3
 infiltrating lobular
 carcinoma 363
 medullary carcinoma
 366–7
- metaplastic carcinoma
 367–8
- metastatic malignant
 neoplasms, liver 481
- mucinous (colloid)
 carcinoma 365–6
- papillary 356–8
- primary breast carcinoma,
 no special type 360–3
- primary breast carcinoma,
 special types 363–70
- tubular carcinoma 363–5
- cystic renal cell carcinoma
 552
- endometrioid 604–5
- hepatocellular 472–4
- lung
 adenoid cystic 434
 body cavity fluids 99
 large cell 430–2
 large cell neuroendocrine
 433–4
 mucoepidermoid 435
 small cell carcinoma 432–3
- squamous cell carcinoma
 428–30
- medullary thyroid 270–2
- ovary 602–3
 clear cell 605
 mucinous cystadenoma
 602–3
 serous cystadenoma 600–2
- parathyroid 284–5
- renal pelvis urothelial
 carcinoma 566–7
- urothelial 170–4
 fine-needle aspiration of
 175–8
 high-grade urothelial
 carcinoma 171–4
 low-grade urothelial
 carcinoma 170
- carcinoma ex-pleomorphic
 adenoma (Ca exPA)
 329–30
- carcinosarcoma
 malignant mixed Mullerian
 tumor 23–4
 of Mullerian origin 106
- carotid body tumor
 (paraganglioma) 293–4
- mediastinum 455–6
- thymic neuroendocrine
 carcinoma vs. 446
- carpet beetle larval parts, in Pap
 smear 13
- cat scratch disease 399–400
- lymphadenitis vs. 396
- catheterized urine specimens
 165
- CD1a 444, 448, 518
- CD3 29, 111, 410, 415, 478, 629
- CD4 52, 54, 410, 415
- CD5 144, 405, 406, 407, 408, 410,
 411, 413, 415, 444, 445,
 448
- CD7 410, 448
- CD8 415
- CD10 3, 96, 115, 144, 275, 405,
 406, 407, 408, 411, 413,
 415, 471, 473, 476, 495,
 548, 555, 557, 562, 564,
 566, 571, 579
- CD15 95, 110, 404, 410, 447, 450
- CD19 111, 410, 413, 447
- CD20 29, 111, 133, 141, 144, 147,
 148, 404, 405, 406, 407,
 408, 410, 411, 413, 436,
 444, 447, 478, 629
- CD23 144, 405, 406, 407, 408,
 411, 413, 447
- CD30 111, 113, 404, 410, 413,
 415, 419, 447, 450, 453,
 613, 629, 633
- CD31 468, 477, 481, 516, 541,
 542
- CD34 112, 134, 143, 147, 441,
 448, 468, 471, 473, 476,
 477, 481, 507–8, 516,
 523–4, 525, 541, 542
- CD43 144, 415
- CD45 103, 111, 133, 141, 147,
 148, 395, 404, 414,
 436, 447, 450, 627, 629,
 478580
- CD45Ro 415
- CD56 20, 70, 71, 102, 133, 141,
 147, 271, 293, 413, 415,
 479, 495, 578, 580, 584,
 585, 586
- CD57 133, 141, 147, 415
- CD68 86, 269, 296, 346, 376, 415,
 551, 574, 576
- CD79a 415, 447, 478
- CD99 112, 419, 426, 481, 495,
 511, 517, 523, 535, 578,
 580
- CD117 *see* c-kit
- CDX2 26, 28, 105, 108, 240, 269,
 418, 438, 443, 492, 634
- CEA 26, 28, 67, 72, 95, 100,
 101–5, 107–10, 116, 216,
 266, 271, 418, 439, 442,
 465, 471, 473–4, 488–90,
 492, 496, 555, 564, 566,
 579, 602, 609, 613, 627,
 632, 633
- central nervous system (CNS)
 202–42
- arteriovenous malformation
 215
- astrocytic neoplasms, variants/
 sub-types of 223–5
- gliomatosis cerebri 203
- gliosarcoma 224–5
- pilocytic astrocytoma
 223–4
- small cell glioblastoma
 multiforme 224
- benign cystic lesions 215–17
- colloid cyst of the third
 ventricle 217
- craniopharyngoma 215–16
- epidermoid cyst 216–17
- Rathke's cleft cyst 216
- benign diseases 204–5
- cerebrospinal fluid findings,
 normal 204–5
- demyelinating disease
 (multiple sclerosis)
 214–15
- important considerations
 202–4
- molecular testing 203–4
- WHO updates for
 classification 202–3
- infections 205–8
- bacterial meningitis 206–7
- fungal and cryptococcal
 meningitis 207–8
- parasitic 211–13
- viral 208–11
- introduction 201–2
- low-grade and malignant
 neoplasms 218–23
- anaplastic astrocytoma
 219–21
- astrocytoma tumors
 218–19
- glioblastoma multiforme
 221–3
- medulloblastoma 237–8
- metastatic neoplasms 238–42
- CSF findings 239–40
- needle biopsy findings
 241–2
- parasitic infections 211–13
- cysticercosis 213
- toxoplasmosis 211–13
- pineal tumors 236–8
- medulloblastoma 237–8
- pineoblastoma 236–7
- pineocytoma 236
- primary neoplasms,
 miscellaneous 225–31
- atypical teratoid/rhabdoid
 tumors 229–30
- choroid plexus papilloma/
 carcinoma 228
- ependymoma 225–6
- germ cell tumors 230–1
- meningioma 227–8
- myxopapillary
 ependymoma 226–7
- pseudo-tumoral macrophage-
 rich lesions 213–14
- small round blue cell tumors
 231–6
- central neurocytoma
 235–6
- lymphoma/leukemia
 231–4
- oligodendroglioma 234
- stereotactic needle biopsy
 technique 202
- subacute cerebral infarction
 214
- viral infections 208–11
- cytomegalovirus 211
- herpes virus 210–11
- Mollaret meningitis 211

- progressive multifocal leukoencephalopathy 209–10
subacute sclerosing panencephalitis 210
viral meningitis 208–9
central neurocytoma 235–6
cerebrospinal fluid 180–8
bacterial meningitis 180–1
findings, normal 204–5
fungal meningitis 181–2
glioblastoma multiforme 187–8
leptomeningeal carcinomatosis 184–5
leukemic/lymphomatous meningitis 183–4
medulloblastoma 186–7
parasitic infections 182–3
viral meningitis 181
see also central nervous system (CNS)
cervical cancer screening 2
cervical carcinoma, of Mullerian origin 106
neuroendocrine 20–1
papillary squamo-transitional cell 19–20
cervical dysplasia 29
Charcot-Leyden crystals, in exfoliative pulmonary cytology 47–8
chemotherapy-associated atypia 138
adenocarcinoma *vs.* 132–3, 138
chemotherapy, effects of
chemotherapy-associated atypia 138
chemotherapy-related esophagitis 126–7
respiratory system 60–1
stomach 138
urine 170
chest wall contaminants 425
Chlamydia trachomatis
lymphocytic cervicitis 5
in Pap smear 10–11
cholangiocarcinoma (bile duct carcinoma) 110, 474–5
hepatocellular carcinoma *vs.* 473
mixed hepatocellular/cholangiocarcinoma 473
chondroblastic osteosarcoma, chondrosarcoma *vs.* 538
chondroblastoma
aneurysmal bone cyst *vs.* 533
giant cell tumor of bone *vs.* 533
osteoclast-rich osteosarcoma *vs.* 533
soft tissue and bone 532–3
chondrosarcoma
chondroblastic osteosarcoma *vs.* 538
chordoma *vs.* 538
enchondroma *vs.* 538
myxoid 510
osteosarcoma *vs.* 540
soft tissue and bone 537–9
chordoma
chondrosarcoma *vs.* 538, 539
enchondroma *vs.* 537
mucin-rich adenocarcinoma *vs.* 539
soft tissue and bone 539
choriocarcinoma 615
choroid plexus papilloma/carcinoma 228
chromogranins 20, 70, 71, 102, 133, 141, 175, 229, 236, 241, 271, 284, 395, 414, 419, 430, 432, 479, 586, 624
chromophobe renal cell carcinoma 561–3
oncocytoma *vs.* 562
renal hybrid oncocytic tumor *vs.* 563
chronic lymphocytic leukemia 405
chronic lymphocytic (Hashimoto's) thyroiditis 255–6
chronic pancreatitis 486–7
chronic sclerosing sialadenitis 308–9
ciliocytophthoria 40
CIN *see* cervical dysplasia
cirrhosis, effusions 90–1
cirrhotic nodules 471–2
CK 5/6 171, 368, 609, 626, 629, 632
CK 19 290, 418, 465, 470, 474
CK 20 27, 171, 178, 293, 418, 474, 603, 609, 632
CK 34BE12 368
CK7 171, 178, 418, 465, 470, 474, 609, 632
CKs 580, 582, 632
clear cell carcinoma
metastatic 605
ovary 605
clear cell renal cell carcinoma 554–7
adrenal cortical carcinoma *vs.* 557
angiomyolipoma *vs.* 557
malakoplakia *vs.* 557
oncocytoma *vs.* 556
renal infarct *vs.* 557
urothelial carcinoma *vs.* 557
xanthogranulomatous pyelonephritis *vs.* 557
clear cell sarcoma
kidney 582–3
soft tissues 515–16
clear cell tumors of unknown origin 627–8
Coccidioides immitis 56–8
collagenous spherulosis 350–1
collecting duct renal cell carcinoma 563–4
metastatic carcinoma *vs.* 564
papillary renal cell carcinoma *vs.* 564
renal medullary renal cell carcinoma *vs.* 564
renal pelvis urothelial carcinoma *vs.* 566
urothelial carcinoma *vs.* 564
colloid (mucinous) carcinoma 365–6
colloid cyst of the third ventricle 217
colloid nodule, thyroid 252–5
colonic adenocarcinoma 108
liver 479
on Pap smear 26–7
congenital ciliated hepatic foregut cyst (CHFC) 464–5
congenital mesoblastic nephroma 554
Congo red 48, 51, 74, 75, 259, 271, 468
corpora amylacea, in exfoliative pulmonary cytology 48–9
corpus luteum cyst 598–9
endometriotic cyst *vs.* 599
follicular cyst *vs.* 599
craniopharyngoma 215–16
Creola bodies (bronchial cell hyperplasia) 42–3
Cruschmann spirals, in exfoliative pulmonary cytology 47, 48
CRxA-01 98
cryptococcal meningitis 207–8
Cryptococcus spp. 56–7
meningitis 207–8
Cryptosporidium spp., duodenum 145
cyclin D1 331, 378, 405, 406, 408, 414, 415
cyclophosphamide 170
cystic BLL (benign lymphoepithelial cyst) 309–11
Warthin's tumor *vs.* 321
cystic metastases, cystic squamous cell carcinoma 288–9
cystic nephroma 553
cyst *vs.* 553
cystic partially differentiated nephroblastoma *vs.* 553
cystic renal cell carcinoma *vs.* 553
cystic papillary thyroid carcinoma metastasis 289–90
cystic partially differentiated nephroblastoma 553
cystic nephroma *vs.* 553
mixed epithelial stromal tumor *vs.* 554
nephroblastoma *vs.* 553
cystic renal cell carcinoma 552
cystic nephroma *vs.* 553
cystic squamous cell carcinoma 288–9
cystic thymoma 444
cysticercosis 213
cysticercosis, central nervous system 213
cystitis glandularis, bladder adenocarcinoma *vs.* 174
cysts
benign lymphoepithelial (cystic BLL) 309–11, 321
branchial cleft 285–7, 290
breast 349–50
colloid cyst of 3rd ventricle 217
dermoid 288
epidermal inclusion
breast 349, 350
head/neck 287–9
epidermoid 216–17
kidney 550–2
liver
congenital ciliated hepatic foregut 464–5
hydatid 465–6
simple 464
mediastinum 443
mucus retention 312–13
ovarian
corpus luteum 598–9
cortical inclusion 602
endometriotic 599–600
follicular 597–8
serous cystadenoma 600–2
pancreatic
dermoid 489
lymphoepithelial 489
mucinous 491–2
parathyroid 282–3
Rathke's cleft 216
salivary duct 310
thymus 443
thyroglossal duct 253, 287–8
cytokeratins *see* CKs
cytomegalovirus (CMV)
central nervous system 211
duodenum 145
esophagitis 126
herpetic esophagitis *vs.* 125
in Pap smear 7–8
urinary tract infection 167
cytomorphologic/architectural patterns 622–30
clear cell 627–8, 630
high grade columnar/ductal adenocarcinoma 624, 625
large cell/polygonal, cohesive 629, 631
large cell/polygonal, non-cohesive 629, 632
low grade columnar/ductal adenocarcinoma 624
microacinar/microfollicular complexes 624–9

Index

- cytomorphologic/architectural patterns (*cont.*)
 miscellaneous 631
 morphologic patterns of
 metastatic malignancies 622–4
 mucinous neoplasms 625, 627
 oncocytic/granular 627, 630
 papillary configuration 625, 628
 pleomorphic/giant cell 628–9, 630
 small cell, cohesive 626, 628
 small cell, non-cohesive 626–7, 629
 spindle cell 629–30, 631
- de Quervain's (granulomatous) thyroiditis 257–8
 acute thyroiditis *vs.* 257
 Riedel's thyroiditis *vs.* 258
- dedifferentiated liposarcoma 510, 511
- demyelinating disease (multiple sclerosis) 214–15
- dermatofibrosarcoma
 protuberans 523–4
 fibrosarcoma *vs.* 525
 tenosynovial giant cell tumor *vs.* 531
- dermoid cysts 288
- desmin 85, 96, 118, 296, 372, 373, 375, 377, 419, 481, 513, 517, 519, 523, 525, 528, 535, 536, 554, 572
- desmoid tumors, abdominal and extra-abdominal *see* fibromatosis
- desmoplastic small round cell tumor, small round cell tumors *vs.* 581
- detached ciliary tufts (DCT) 86–7
- diethylstilbestrol (DES) 2, 22
- differential cytokeratins 632–3
- diffuse large B-cell lymphoma 408–9
- diffuse tenosynovial giant cell tumor 530–1
- Dpc4 105, 108, 109
- D2-40 95
- ductal adenocarcinoma, pancreas 492–4
- ductal carcinoma in situ (DCIS) 358–9
- ductal carcinoma of breast 358, 359, 362
- ductal lavage, breast 341–2
- duodenal tumors 145–9
 adenocarcinoma 146
 GIST 147–8, 149
 infectious agents 145
 lymphoma 148–9
 neuroendocrine tumor 147
 peptic ulcer disease 145
 small cell carcinoma 148
- dust cells (carbon-laden histiocytes) 46
- dysgerminoma *see* seminoma (dysgerminoma)
- dysplasia
 anus 152–4
 Barrett's esophagus 129–30
 cervix 15, 16, 29
 liver 471–2
 stomach 137–8
- E-cadherin 96, 360, 571
- effusions 83–92
 bacterial infections 89
 cirrhosis 90–1
 detached ciliary tufts 86–7
 eosinophilic 87
 exudate fluids 83
 fungal/parasitic infections 90
 hematopoietic cells 86
 infarction 92
 macrophages 86
 mesothelial cells, from normal to reactive 83–6
 quiescent 83–5
 reactive 85–6
 pancreatitis 91–2
 rheumatoid pleuritis 88
 SLE- associated 88–9
 transudate fluids 83
 tuberculous 89
 uremia 91
 viral infections 89–90
- elastin fibers, in exfoliative pulmonary cytology 50–1
- elastofibroma 520–1
- EMA 48, 72, 85, 96, 110, 111, 112, 115, 116, 187, 225, 228, 229, 377, 380, 415, 419, 441, 452, 465, 470, 474, 476, 511, 513, 517, 528, 539, 555, 557, 579, 582, 584, 585, 602, 605, 607, 608, 610, 612, 615, 620, 625, 629, 632, 633
- embryonal carcinoma 614
 yolk sac tumor *vs.* 615
- embryonal rhabdomyosarcoma 535–7
- enchondroma 537
 chondrosarcoma *vs.* 537
 chordoma *vs.* 537
 soft tissue and bone 537
- endocervical adenocarcinoma 21–2
- endocervical glands, HSIL involving 18, 19, 21
- endocervix
 adenocarcinoma 21–2
 adenocarcinoma-*in-situ* 21
- endometrial adenocarcinoma 22–3
- endometrial cells 2–3
- endometrioid carcinoma 604–5
- endometriosis, large intestine adenoma/adenocarcinoma *vs.* 152
- endometriotic cyst 599–600
- endometrioid adenocarcinoma 22–3, 105–6
 corpus luteum cyst *vs.* 599
 serous cystadenoma/ carcinoma *vs.* 602
- endophthalmitis
 bacterial 190–1
 fungal 191
 viral 191–2
- eosinophils
 effusions 87
 respiratory system 47
- ependymoma 225–6
 myxopapillary 226–7
- epidermal inclusion cyst
 branchial cleft cyst *vs.* 287
 breast 346
 squamous cell carcinoma *vs.* 350
 cystic squamous cell carcinoma *vs.* 288
 head/neck 288
 thyroglossal duct cyst *vs.* 287
- epidermoid carcinoma 63–5
- epidermoid cyst 216–17
- epidermoid inclusion cysts/dermoid cysts 288
- epididymitis 610
- epithelial membrane antigen (EMA) expression *see* EMA
- epithelial-myoepithelial carcinoma 327–8
 adenocarcinoma NOS *vs.* 328
 adenoid cystic carcinoma *vs.* 328
 polymorphous adenocarcinoma *vs.* 327
- epithelioid
 hemangioendothelioma 477–8
- epithelioid sarcoma 514–15
 clear cell carcinoma *vs.* 516
 extrarenal rhabdoid tumor *vs.* 517
- esophageal carcinoma 107
- esophagus 129–35
 adenocarcinoma 131–3
 squamous cell carcinoma *vs.* 131
 Barrett's esophagus 127–9
 GERD *vs.* 127
Candida esophagitis 123–4
 carcinoma 107
 cytomegalovirus esophagitis 126
 dysplasia in Barrett's 129–30
 GERD 127
 GIST 142–3
 herpetic esophagitis 124–6
 leiomyoma 134–5
 leiomyosarcoma 134
- lymphoma 133–4
 radiation- and chemotherapy-related esophagitis 126–7
 small cell carcinoma 133–4
 squamous cell carcinoma 130–1
- estrogen receptor 98, 360, 633
- Ewing's sarcoma (ES)/primitive neuroectodermal tumor (PNET) 534–5
 embryonal/alveolar rhabdomyosarcoma *vs.* 537
 lymphoma *vs.* 535
 rhabdomyosarcoma *vs.* 535
 small round cell tumors *vs.* 626
 soft tissue and bone 534–5
 synovial sarcoma *vs.* 516
- exfoliative pulmonary cytology 37–75
 aspiration pneumonia 54
 bronchial cell hyperplasia (Creola bodies) 42–3
 bronchoscopic specimens 38
 cells within alveolar spaces
 carbon-laden histiocytes 46
 hemosiderin-laden macrophages 45–6
 inflammatory cells 47
 multinucleated giant cells 46–7
 pulmonary (alveolar) macrophages 45
 vacuolated histiocytes 46
- Charcot-Leyden crystals 47–8
- corpora amylacea 48–9
- Cruschmann's spirals 47
- elastin fibers 50–1
- ferruginous bodies 50
- goblet cell hyperplasia 41
- inflammatory cells
 eosinophils 47
 lymphocytes 47
 neutrophils 47
- lung transplant patients 53–4
- malignant neoplasms 62–74
 ADC-LP/AIS 68–9
 hematopoietic malignancies 73–4
 invasive bronchogenic adenocarcinoma 65–8
 large cell carcinoma 72–3
 neuroendocrine tumors 69–72
 squamous cell carcinoma 63–5
- methods of 37–8
 bronchoscopic specimens (brush, wash, and lavage) 38
 sputum 37–8
 neuroendocrine tumors 69–72
 psammoma bodies and calcospherites 49

- pulmonary alveolar microlithiasis 49–50
- pulmonary native cells, from normal to reactive 38–47
- alveolar lining cells 43–5
- bronchial cell hyperplasia (Creola bodies) 42–3
- cells within alveolar spaces 45–6
- goblet cell hyperplasia 41
- inflammatory cells 47
- multinucleated giant cells 46–7
- reactive and reparative bronchial cell changes 40–1
- reserve cell hyperplasia 42–3, 426
- squamous cells 38–9
- tracheobronchial lining cells 39–40
- pulmonary-related diseases 51–3
- alveolar proteinosis 51–2
- infarct/embolism 53
- sarcoidosis 52–3
- rare lesions, miscellaneous 74–5
- amyloidosis 74–5
- salivary gland analog tumors 75
- respiratory infections 54–60
- Actinomyces* 55
- bacterial pneumonia 55
- Candida* 55
- fungal infections 55–8
- mycobacterial infection 55
- Pneumocystis jiroveci* 58–9
- viral infections 59–60
- salivary gland analog tumors 75
- sputum 37–8
- therapy-related changes 60–2
- amiodarone lung 60
- chemotherapy 60–1
- radiation therapy 61–2
- tracheobronchial lining cells 39–40
- “exodus” cells 3
- extra-abdominal desmoid tumors *see* fibromatosis
- extrarenal rhabdoid tumor 516–17
- clear cell carcinoma *vs.* 516
- epithelioid sarcoma *vs.* 517
- extrauterine/metastatic malignancies 24–9
- breast adenocarcinoma 25–6
- colon adenocarcinoma 26–7
- gastric adenocarcinoma 26
- lymphoma 29
- malignant melanoma 28
- Paget’s disease of the vulva 27–8
- serous carcinoma from either ovary or fallopian tube 24–5
- urothelial cell carcinoma 27
- exudate fluids 83
- fallopian tube, serous carcinoma 24–5
- fasciitis
- nodular (*see* nodular fasciitis)
- proliferative, soft tissue and bone 518–19, 520
- fat necrosis
- inflammatory breast lesions 347–8
- liposarcoma *vs.* 510
- ferruginous bodies, in exfoliative pulmonary cytology 50
- fibroadenoma 370–1
- fibroblastoma, giant cell *see* giant cell fibroblastoma
- fibroepithelial tumors, breast 370–3
- fibroadenoma 370–1
- Phyllodes tumor 371–3
- fibroma of ovary 608
- fibromatosis 521–2
- breast 373
- metaplastic carcinoma *vs.* 373
- myofibroblastoma *vs.* 375
- dermatofibrosarcoma protuberans *vs.* 524
- fibrosarcoma *vs.* 525
- head and neck lesions 294–5
- leiomyosarcoma *vs.* 528
- myositis ossificans *vs.* 520
- peripheral nerve sheath tumor *vs.* 527
- pseudosarcomatous spindle cell lesions *vs.* 519
- schwannoma *vs.* 526
- solitary fibrous tumor *vs.* 523
- fibrosarcoma 524–5
- dermatofibrosarcoma protuberans *vs.* 525
- fibromatosis *vs.* 525
- giant cell fibroblastoma *vs.* 525
- leiomyosarcoma *vs.* 528
- peripheral nerve sheath tumor *vs.* 527
- solitary fibrous tumor *vs.* 525
- synovial sarcoma *vs.* 512
- fine-needle aspiration (FNA)
- of breast 340–1
- of central nervous system 241–2
- of lymph nodes 389–90
- of malignancies of unknown primary site 620–1
- stereotactic needle biopsy technique 202
- of thyroid 252
- of urothelial cell carcinoma 175–8
- flow cytometry 413, 436
- fluorescence in situ hybridization (FISH) 305, 367, 557
- focal fatty change, in liver 467–8
- focal nodular hyperplasia (FNH) 469–70
- follicular center lymphoma
- benign lymphoepithelial cyst *vs.* 310
- chronic sclerosing sialadenitis *vs.* 308
- follicular cyst, ovary 597–8
- follicular lesion, thyroid 260–2
- follicular lymphoma 407–8
- follicular neoplasm, thyroid gland 262–3
- follicular nodule, thyroid 252–5
- fungal endophthalmitis 191
- fungal infections
- effusions 90
- respiratory 55–8
- urinary tract 167–9
- see also specific fungal infections*
- fungal meningitis 181–2, 207–8
- galactocele, pregnancy changes *vs.* 354
- ganglion cyst, intramuscular myxoma *vs.* 534
- ganglioneuroblastoma 456–7
- ganglioneuroma *vs.* 456
- ganglioneuroma 456
- Gardnerella vaginalis* 4, 7
- in Pap smear 9
- gastric adenocarcinoma 26, 107–10, 138–40, 481
- bile duct (cholangiocarcinoma) 110
- carcinoid tumor *vs.* 142
- colonic adenocarcinoma 108
- diffuse form 152
- hepatocellular carcinoma 110
- lymphoma *vs.* 144
- pancreatic adenocarcinoma 109–10
- on Pap smear 26
- pseudomyxoma peritonei 110
- gastric dysplasia 137–8
- polyps *vs.* 138
- gastric polyps 138
- gastric tumors
- adenocarcinoma 26, 107–8, 138–40, 144
- carcinoid 145–9
- granular cell 143
- leiomyoma 143
- leiomyosarcoma 143
- lymphoma 143–4
- neuroendocrine 140–2
- stromal, lymphoma *vs.* 144
- gastric xanthoma, adenocarcinoma *vs.* 140
- gastritis 135–6
- gastroesophageal reflux disease (GERD) 127
- gastrointestinal stromal tumor (GIST)
- duodenum 147–8, 149
- gastric 147–8, 149
- leiomyoma *vs.* 143
- stomach 142–3
- gastrointestinal (GI) tract 129–54
- anus 152–4
- squamous dysplasia and HPV 152–4
- duodenum 145–9
- adenocarcinoma 146
- GIST 147–8, 149
- infectious agents 145
- lymphoma 148–9
- neuroendocrine tumor 147
- peptic ulcer 145
- esophagus 129–35
- adenocarcinoma 131–3
- Barrett’s esophagus 127–9
- Candida* esophagitis 123–4
- cytomegalovirus esophagitis 126
- dysplasia in Barrett’s 129–30
- GERD 127
- herpetic esophagitis 124–6
- leiomyoma and other mesenchymal tumors 134–5
- radiation- and chemotherapy-related esophagitis 126–7
- small cell carcinoma 133–4
- squamous cell carcinoma 130–1
- large intestine 149–52
- adenomas and adenocarcinoma 150–2
- inflammatory bowel disease 149–50
- stomach 135–44
- adenocarcinoma 138–40
- chemotherapy-associated atypia 138
- dysplasia 137–8
- gastritis 135–6
- GIST 142–3
- lymphoma 143–4
- neuroendocrine tumor 140–2
- peptic ulcer disease 136–7
- polyps 138
- tumors 106–7
- gastrointestinal (GI) tumors 106–7
- GATA3 108, 325, 418, 438, 443, 499, 566, 579, 627
- GCDFP-15 25, 98, 369, 380, 418, 499, 634
- gene expression profiling 413
- GERD *see* gastroesophageal reflux disease (GERD)
- germ cell tumors
- body cavity fluids 112–14
- central nervous system 230–1
- gonads 612–16
- choriocarcinoma 615
- embryonal carcinoma 614
- seminoma 612–13

Index

- germ cell tumors (*cont.*)
 spermatocytic seminoma 613–14
 teratoma 615–16
 yolk sac tumor 614–15
 lymph node metastases 636
 mediastinum 452–3
 thymic, thymic carcinoma *vs.* 446
see also choriocarcinoma; embryonal carcinoma; teratoma; yolk sac tumor
- GFAP 186, 187, 218, 220, 224, 225, 226, 234, 235, 238, 242, 512
- giant cell fibroblastoma 523–4
 fibrosarcoma *vs.* 525
- giant cell tumor of bone 531–2
 aneurysmal bone cyst *vs.* 532
 chondroblastoma *vs.* 533
 giant cell-rich osteosarcoma *vs.* 532
 tenosynovial giant cell tumor *vs.* 531
- giant cells, multinucleated 46–7
Giardia lamblia/giardiasis 145
- GIST *see* gastrointestinal stromal tumor (GIST)
- glaucoma, phacolytic 189–90
- glioblastoma multiforme (GBM) 187–8, 221–3
 small cell 224–5
- gliosarcoma 224–5
- glomus tumor, carcinoid tumor *vs.* 142
- GLUT-1 95, 286, 490
- glypican-3 453, 473, 475, 476
- goblet cell hyperplasia 41
- goiter
 amyloid 259
 diffuse hyperplastic 256
 nodular, parathyroid adenoma *vs.* 284
- “golf ball” cells 7
- Gomori methenamine silver 123, 182, 423
- gonadal tumors 597–616
 germ cell tumors 612–16
 choriocarcinoma 615
 embryonal carcinoma 614
 seminoma 612–13
 spermatocytic seminoma 613–14
 teratoma 615–16
 yolk sac tumor 614–15
- ovarian 597–609
 Brenner tumor 603–4
 clear cell carcinoma 605
 corpus luteum cyst 598–9
 cystic granulosa cell tumor, follicular cyst *vs.* 598
 dysgerminoma 606
 endometrioid carcinoma 604–5
 endometriotic cyst 599–600
 fibroma/thecoma 608
- follicular cyst 597–8
- granulosa cell tumor (adult and juvenile types) 606–8
 metastatic tumors 609
 mucinous cystadenoma and carcinoma 602–3
 serous cystadenoma and carcinoma 600–2
 stromal tumors 611–12
 Leydig cell tumor 611–12
 Sertoli cell tumor 612
- testis 609–11
 adenomatoid tumor 610–11
 epididymitis/orchitis 610
 hematocele 610
 hydrocele 609
 lymphoma 611
 seminoma 612–13
 spermatocele 609–10
 spermatocytic seminoma 613–14
- gonorrhea 4
- granular cell tumor
 breast 375–7
 malignant mesenchymal tumors (sarcomas) 376–7
 GIST *vs.* 143
 soft tissue and bone 512–13
 alveolar soft part sarcoma *vs.* 513
- granulocytic sarcoma 412
- granulomas
 liver 467
 lung, caseating 423
 malignancies associated with 631–2
 silicone 348
- granulomatous inflammation
 lung 423–5, 438
 soft tissue and bone 515
- granulomatous lymphadenitis 397–9
- granulomatous sialadenitis 309
- granulomatous (de Quervain’s) thyroiditis 257–8
 acute thyroiditis *vs.* 257
 Riedel’s thyroiditis *vs.* 258
- granulosa cell tumor 606–8
 Brenner tumor *vs.* 603
- Graves’ disease 258–9
- gynecomastia 380–1
- hamartoma
 bile duct 470–1
 lung 425–7, 438
- Hashimoto’s (chronic lymphocytic) thyroiditis 255–6
 granulomatous (de Quervain’s) thyroiditis *vs.* 258
 Graves’ disease *vs.* 259
 Hürthle cell neoplasm *vs.* 264
 lymphoma *vs.* 274
 Riedel’s thyroiditis *vs.* 258
- head and neck lesions,
 miscellaneous 285–99
 branchial cleft cyst 285–7
 cystic metastases 288–9
 cystic papillary thyroid carcinoma metastasis 289–90
 cystic squamous cell carcinoma 288–9
 epidermoid inclusion cysts/dermoid cysts 288
 fibromatosis 294–5
 lipoma 298–9
 Merkel cell carcinoma 292–3
 nasopharyngeal carcinoma 291–2
 nodular fasciitis 296–7
 paraganglioma (carotid body tumor) 293–4
 pilomatrixoma (calcifying epithelioma of Malherbe) 295–6
 schwannoma 297–8
 thyroglossal duct cyst 287–8
see also parathyroid gland; thyroid gland
- hemangioma
 angiosarcoma *vs.* 541
 Kaposi’s sarcoma *vs.* 541
 liver 468–9
 soft tissue and bone 540–1
- hematocele 610
- hematopoietic cells, effusions 86
- hematopoietic malignancies (HPM) 73–4
- hematopoietic neoplasms (lymphoma and leukemia) 110–12
 primary effusion lymphoma 111–12
- hemorrhage, intraocular 188
- hemosiderin 464
- hemosiderin-laden macrophages 45–6
- Hep Par-1 110, 129, 634
- hepatoblastoma 475–6
- hepatocellular adenoma 470
- hepatocellular carcinoma (HCC) 110, 472–4
 adrenal cortical adenoma/hyperplasia *vs.* 584
 clear cell 472–3
 fibrolamellar 473
 hepatoblastoma *vs.* 476
 oncocytic 473
 pleomorphic/giant cell 473
 pseudoglandular/acinar 473
 sarcomatoid/spindle cell/pseudosarcomatous 473
 sclerotic 473
- hepatocytes 464
- herpes simplex virus (HSV)
 central nervous system 210–11
 in Pap smear 6–7
- herpetic esophagitis 124–6
 cytomegalovirus *vs.* 125
- squamous cell carcinoma *vs.* 125, 131
- Herxheimer’s spirals 64, 101
- heterotopic pancreas, carcinoid tumor *vs.* 142
- high-grade myxoid liposarcoma 509
- high-grade sarcomas, on Pap smear 24
- high-grade squamous intraepithelial lesions (HSIL) 16–18
 anus 153
 endocervical glands 18
- high-grade urothelial carcinoma 171–4
- histiocytes
 carbon-laden 46
 vacuolated 46
- histiocytic sarcoma 412
- Histoplasma capsulatum* 56
- HIV-associated
 lymphadenopathy, lymphoma *vs.* 332
- HMB-45 28, 73, 114, 194, 275, 380, 395, 414, 419, 481, 512, 515, 516, 572, 627, 629
- Hodgkin lymphoma
 lymph nodes 402–4
 mediastinal 449–50
 mediastinal B-cell lymphoma *vs.* 448
 mediastinal seminoma *vs.* 452
- nasopharyngeal carcinoma *vs.* 291
- systemic, mediastinum involvement 450
- thymoma *vs.* 445
- HPV *see* human papilloma virus (HPV)
- human papilloma virus (HPV)
 anal dysplasia 152–4
 testing, Pap smear 2
- Hürthle cell (oncocytic) neoplasms 263–5
 medullary thyroid carcinoma *vs.* 272
- Hürthle cells 252
- hyaline globules,
 intracytoplasmic 631
- hyalinizing trabecular adenoma 270
- hydatid cyst 465–6
- hydrocele 609
- hyperkeratosis 5
- hyperplasia
 adenomatous 471–2
 adrenal cortical 583–6
 alveolar lining cells 43–5
 bronchial cell 42–3
 Brunner’s gland 147
 focal nodular hyperplasia 469–70
 goblet cell 41

- interparotid lymph node 332
intraductal 358
liver, focal nodular 469–70
mesothelial 440
parathyroid 284
pneumocyte type II 43–5
reactive lymphoid 400–2, 404, 408
reserve cell 41–3, 426
thymic 444
hyperplastic nodule, thyroid 252–5
- idiopathic chronic uveitis 193
IgD 415
ileal conduit specimens 166
immunohistochemistry (IHC) approach to MUP 632
immunoperoxidase 202
in-situ lesions of the breast 358–60
ductal carcinoma in situ 358–9
lobular neoplasia 360
India ink 208
infarction
effusions 92
subacute cerebral 214
infections *se also specific infections and agents*
central nervous system 205–8
bacterial meningitis 206–7
fungal and cryptococcal meningitis 207–8
duodenum 145–9
liver 466
respiratory system 54–60
infectious agents
duodenum 145
urinary cytology 167–9
infectious cysts, liver 465–7
abscess/infections/pyogenic abscesses 466
amoebic abscesses 466
hydatid cyst 465–6
malaria 467
Penicillium marneffeii 467
infiltrating ductal carcinoma 360–3
infiltrating lobular carcinoma 363
inflammatory bowel disease (IBD) 149–50
inflammatory breast lesions 345–9
fat necrosis 347–8
mastitis 345–6
silicone-related changes 348–9
subareolar abscess 346–7
inflammatory cells 47
inflammatory conditions, urinary cytology 166–9
noninfectious 166
other infectious agents 167–9
polyoma virus 166–7
inflammatory myofibroblastic tumor 437
- inhibin 584, 585, 586, 603, 607, 612, 615, 634
INI-1 515, 517
insular thyroid carcinoma 272–3
international system for serous effusions cytopathology 82–3
intracytoplasmic hyaline globules 631
intraductal papillary mucinous neoplasm (IPMN) 491–2
intramammary lymph node 367, 378
intramuscular lipoma 507
intramuscular myxoma 533–4
ganglion cyst *vs.* 534
myxoid liposarcoma *vs.* 534
intranuclear inclusions 631
intraocular cytology 188–98
asteroid hyalosis 189
bacterial endophthalmitis 190–1
fungal endophthalmitis 191
idiopathic chronic uveitis 193
intraocular hemorrhage 188
lymphoma 194–6
malignant melanoma 193–4
melanoma 193–4
metastatic carcinoma 198
phacolytic glaucoma 189–90
primary intraocular malignant lymphoma 194–6
retinoblastoma 196–7
toxocara 192–3
toxoplasmosis 192
viral endophthalmitis 191–2
intraocular hemorrhage 188
intraparotid lymph node 312
chronic sclerosing sialadenitis *vs.* 309
hyperplasia, lymphoma *vs.* 331
intrauterine contraceptive device (IUD), reactive cellular changes 4, 5
invasive bronchogenic adenocarcinoma (ADC) 65–8
iron 464
K903 100–1, 110
Kaposi's sarcoma, hemangioma *vs.* 541
Kappa immunostain 29, 415
karyomegalic interstitial nephritis 172
keratinizing squamous cell carcinoma 18–19
keratins 94, 140, 368, 373, 377, 380, 477, 478, 555, 557, 562, 564, 566, 571
Ki-67 18, 21, 30, 41, 140, 141, 147, 202, 218, 220, 223–4, 236, 284, 315, 330, 378, 408, 411, 415, 477, 479
kidney 548–83
abscess 552
- angiomyolipoma 572–3
clear cell RCC *vs.* 557, 572
liposarcoma *vs.* 572
sarcomatoid RCC *vs.* 565–6, 572
clear cell sarcoma 582–3
cyst
infected 551
simple 550–2
cystic nephroma 553
cystic partially differentiated nephroblastoma 553
immunohistochemical profiles 579
lymphoma 567–9
acute rejection *vs.* 569
small cell carcinoma *vs.* 568
malakoplakia,
xanthogranulomatous pyelonephritis *vs.* 574
MEST 554
metastases, clinical patterns of 639
metastatic carcinoma 569, 571
clear cell RCC *vs.* 569
collecting duct carcinoma *vs.* 569
renal pelvis squamous cell carcinoma *vs.* 569
urothelial carcinoma *vs.* 569
nephroblastoma 577–8
normal/nonneoplastic kidney 548–50
oncocytoma 570, 571–2
chromophobe RCC *vs.* 571
clear cell RCC *vs.* 571
renal abscess 573–4
renal cell carcinoma
chromophobe 561–3
clear cell 554–7
collecting duct 563–4
cystic 552
papillary 557–61
sarcomatoid 564–6
renal malakoplakia 575–7
renal pelvis urothelial carcinoma 566–7
rhabdoid tumor 581–2
extrarenal 516–17
small round cell tumors *vs.* 582
simple cyst 550–2
small round cell tumors of 578–81
immunoprofiles 580
XGP 574–5
Kikuchi-Fujimoto disease, acute lymphadenitis *vs.* 396
koilocytes 15, 152
Kuttner's tumor 308–9
lactational adenoma 348
lactational changes, pregnancy and 353–4
Lambda immunostain 29, 393, 415
- Langerhans' cell histiocytosis 517–18
large B-cell lymphoma 408–9
diffuse 408–9
mediastinum involvement 447
mediastinum 447–8
precursor T-cell lymphoblastic lymphoma *vs.* 449
T-cell rich 410
Hodgkin's lymphoma *vs.* 450
thymoma *vs.* 445
large bone metastases 636
large cell carcinoma (LCC) exfoliative pulmonary cytology 72–3
lung 430–2
large cell neuroendocrine carcinoma (LCNEC) lung 433–4
neuroendocrine tumors 71
large cell undifferentiated carcinoma 430–2
adenocarcinoma *vs.* 431
large cell neuroendocrine carcinoma *vs.* 433
malignant lymphoma *vs.* 436
squamous cell carcinoma *vs.* 430
large intestine 149–52
adenomas and
adenocarcinoma 150–2
inflammatory bowel disease *vs.* 150
inflammatory bowel disease 149–50
LCA 29, 380, 395, 414, 415, 436, 613
leiomyoma
esophagus 134–5
GIST *vs.* 134, 143
mixed epithelial stromal tumor *vs.* 554
sarcomatoid renal cell carcinoma *vs.* 566
stomach 143
leiomyosarcoma
esophagus 134
fibromatosis *vs.* 528
fibrosarcoma *vs.* 528
GIST *vs.* 143
leiomyoma *vs.* 134
pleomorphic rhabdomyosarcoma *vs.* 529
schwannoma *vs.* 298
soft tissue and bone 527–8
solitary fibrous tumor *vs.* 528
stomach 143
leptomeningeal carcinomatosis 184–5
Leptothrix spp., in Pap smear 8–9
leukemia
chronic lymphocytic 405
primary effusion lymphoma 111–12

Index

- leukemia (*cont.*)
 small round blue cell tumors
 231–4
- leukemic/lymphomatous
 meningitis 183–4
- leukocyte common antigen *see*
 LCA
- Leydig cell tumor 611–12
- lipofuscin 464
- lipoma
 breast 374
 head and neck lesions 298–9
 soft tissue and bone 506–8
 intramuscular 507
 liposarcoma *vs.* 510
 myelolipoma 508
 pleomorphic 508
 spindle cell 507–8
- liposarcoma 508–11
 dedifferentiated 510, 511
 high-grade myxoid
 liposarcoma 509
 myxoid 509, 510
 intramuscular myxoma *vs.*
 534
 pleomorphic 509–10
 pleomorphic lipoma *vs.* 508
 round cell 509
 well-differentiated 508–9
 intramuscular lipoma *vs.*
 507
 lipoma *vs.* 507
 spindle cell lipoma *vs.* 507
- liver 463–81
 adenomatous hyperplasia
 471–2
 amyloidosis 468
 benign neoplastic hepatic
 lesions 468–71
 bile duct adenoma/
 hamartoma 470–1
 focal nodular hyperplasia
 469–70
 hemangioma 468–9
 hepatocellular adenoma
 470
 benign non-neoplastic lesions
 464–5
 amoebic cysts 466
 amyloidosis 468
 congenital ciliated hepatic
 foregut cyst 464–5
 granulomas 467
 hydatid cyst 465–6
 nodular regeneration 473–4
 pyogenic abscess 466
 simple cysts 464
 steatosis 467–8
 borderline processes, cytology
 of 471–2
 cirrhotic nodules 471–2
 dysplasia 471–2
 granulomas 467
 infectious cysts 465–7
 abscess/infections/pyogenic
 abscesses 466
 amoebic abscesses 466
 hydatid cyst 465–6
 malaria 467
Penicillium marneffe 467
 introduction 463–4
 lymphoma 478
 malignant neoplasms 472–6
 cholangiocarcinoma 474–5
 hepatoblastoma 475–6
 hepatocellular carcinoma
 472–4
 sarcomas 476–8
 metastases, clinical patterns of
 636–7
 metastatic malignant
 neoplasms 478–80
 adenocarcinoma 473
 breast carcinoma 481
 colonic adenocarcinoma
 479
 gastric adenocarcinoma
 481
 melanoma 481
 metastasis, general 478–9
 neuroendocrine tumor 479
 prostate adenocarcinoma
 481
 sarcoma 481
 small cell carcinoma 479,
 480, 481
 squamous cell carcinoma
 480–1
 normal, cytology of 464
 sarcoma 476–8
 angiosarcoma 476–7
 embryonal sarcoma 476
 epithelioid
 hemangioendothelioma
 477–8
 metastasis 481
 steatosis/focal fatty change
 467–8
 lobular neoplasia 360
 localized tenosynovial giant cell
 tumor 530–1
 low-grade astrocytoma 218–19
 low grade mucoepidermoid
 carcinoma 310, 316, 320,
 322, 326
 low-grade squamous
 intraepithelial lesions
 (LSIL) 15–16
 low-grade urothelial carcinoma
 170
 lung adenocarcinoma 427–8
 large cell undifferentiated
 carcinoma *vs.* 431
 metastatic 428
 squamous cell carcinoma *vs.*
 428, 430
 lung transplant patients 53–4
 lung tumors 422–39
 abscess 422–3
 granulomatous
 inflammation *vs.* 424
 squamous cell carcinoma
vs. 430
 adenocarcinoma 427–8
 adenoid cystic carcinoma
 434–5
 metastatic 434
 basaloid squamous cell
 carcinoma
 large cell neuroendocrine
 carcinoma *vs.* 433
 small cell carcinoma *vs.* 433
 benign mesenchymal tumor,
 sarcoma *vs.* 438
 carcinoid 426–7
 large cell neuroendocrine
 carcinoma *vs.* 434
 sarcoma *vs.* 437
 small cell carcinoma *vs.* 433
 carcinoma
 adenoid cystic 434
 body cavity fluids 99
 large cell 430–2
 large cell neuroendocrine
 433–4
 mucoepidermoid 435
 small cell carcinoma 432–3
 squamous cell carcinoma
 428–30
 caseating granuloma, abscess
vs. 423
 cavitating carcinoma
 abscess *vs.* 423
 granulomatous
 inflammation *vs.* 424
 effusions 89
 granulomatous inflammation
 423–5
 sarcoma *vs.* 438
 hamartoma 425–6
 sarcoma *vs.* 438
 inflammatory myofibroblastic
 tumor 437
 sarcoma *vs.* 438
 large cell neuroendocrine
 carcinoma 433–4
 large cell undifferentiated
 carcinoma 430–2
 adenocarcinoma *vs.* 431
 large cell neuroendocrine
 carcinoma *vs.* 433
 malignant lymphoma *vs.*
 436
 squamous cell carcinoma
vs. 430
 malignant lymphoma 435–7
 metastases, clinical patterns
 of 636
 metastatic malignancy 438–9
 sarcoma 437–8
 lymph nodes 389–419
 ancillary diagnostic
 techniques 412–19
 flow cytometry 413
 fluorescence *in situ*
 hybridization 412–13
 immunohistochemistry
 413–14
 molecular studies in non-
 Hodgkin lymphomas
 414–19
 polymerase chain reaction
 412
 axillary 635
 cervical 635
 cytopathology, introduction to
 389–95
 fine needle aspiration of
 lymph nodes 389–90
 lymph node aspirates,
 practical approach to
 394–5
 normal lymph node 390–4
 fine-needle aspiration 389–90
 practical approach 394–5
 inguinal 636
 intramammary 367, 378
 intraparotid 312
 lymphomas, small cell 405–8
 lymphoproliferative disorders
 402–4
 Hodgkin lymphoma 402–4
 non-Hodgkin lymphoma
 404
 metastases, clinical patterns of
 635–6
 metastatic disease to lymph
 nodes 414–19
 nonneoplastic lymph nodes
 396–402
 acute lymphadenitis 396–7
 cat scratch disease 399–400
 granulomatous
 lymphadenitis 397–9
 reactive hyperplasia 400–2
 silicone-associated
 lymphadenitis 402
 normal 390–4
 supraclavicular 635
 lymphadenitis
 acute 396
 Hodgkin's lymphoma *vs.*
 404
 granulomatous 397–9
 mycobacterial 400
 necrotizing, acute thyroiditis
vs. 257
 silicone-associated 402
 tuberculous 396
 lymphoblastic lymphoma 409
 lymphocytes, respiratory system
 47
 lymphocytic cervicitis 5
 lymphoepithelial cyst, pancreas
 489
 lymphoepithelial sialadenitis
 311–12
 lymphoid lesions, ancillary
 techniques for diagnosis
 of 412–19
 immunohistochemistry
 in non-Hodgkin
 lymphomas 413–14
 molecular studies in non-
 Hodgkin lymphomas
 414–19
 lymphoma
 bladder 178

- breast 377–9
central nervous system 231–4
duodenum 148–9
embryonal/alveolar
 rhabdomyosarcoma *vs.*
 537
esophagus, small cell
 carcinoma *vs.* 133–4
Ewing's sarcoma *vs.* 535
follicular center 308, 310
gastric 148–9
 carcinoid tumor *vs.* 147, 148
Hodgkin's 111, 291, 378, 395,
 402–4
 mediastinum 449–50
intraocular 194–6
kidney 567–9
large B-cell 408–9
 diffuse 408–9
 mediastinum 447–8
 T-cell rich 410, 450
large cell malignant 435–7
liver 478
lung 435–7
lymphoblastic 409–10
medium to large cell 408–12
 anaplastic large cell
 lymphoma 410–11
 Burkitt lymphoma 411–12
 diffuse large B-cell
 lymphoma 408–9
 peripheral T-cell
 lymphoma, NOS 410
 precursor T and B-cell
 lymphoblastic
 lymphomas 409–10
melanoma, large cell
 undifferentiated
 carcinoma *vs.* 431
metastatic 438–9
 poorly differentiated 431
 sarcoma 438
mucoepidermoid carcinoma
 435
 metastatic 435
non-Hodgkin's 404, 413–14
on Pap smear 29
pleomorphic adenoma,
 adenoid cystic
 carcinoma *vs.* 434
primary effusion lymphoma
 111–12
renal 567–9
 acute rejection *vs.* 569
 small cell carcinoma *vs.* 568
 urothelial carcinoma *vs.* 178
salivary glands 331–2
sarcoma 437–8
 inflammatory
 myofibroblastic tumor
 vs. 437
 metastatic 438
sarcomatoid carcinoma
 inflammatory
 myofibroblastic tumor
 vs. 437
 sarcoma *vs.* 438
sclerosing hemangioma,
 inflammatory
 myofibroblastic tumor
 vs. 437
small cell 405–8
 follicular lymphoma 407–8
 mantle cell lymphoma
 405–7
 marginal zone lymphoma
 407
 small lymphocytic
 lymphoma/chronic
 lymphocytic leukemia
 405
small cell carcinoma 432–3
 adenocarcinoma *vs.* 428
 carcinoid *vs.* 427
 large cell neuroendocrine
 carcinoma *vs.* 434
 malignant lymphoma *vs.*
 436
 squamous cell carcinoma
 vs. 430
small round blue cell tumors
 231–4
squamous cell carcinoma
 428–30
 large cell undifferentiated
 carcinoma *vs.* 430
 mucoepidermoid
 carcinoma *vs.* 435
stomach 143–4
T-cell, peripheral 410
testis 611
 spermatocytic seminoma
 vs. 613
thyroid gland 274–5
 Hashimoto's thyroiditis *vs.*
 256
 poorly differentiated
 thyroid carcinoma *vs.*
 273
 of unknown origin 622
lymphomatous meningitis 183–4
lymphoproliferative disorders
 402–4
Hodgkin lymphoma 402–4
metastatic tumors 414–19, 609
 carcinomas 415
 germ cell tumors 415
 melanoma 416, 417
 sarcoma 418
non-Hodgkin lymphoma 404
non-neoplastic lymph nodes
 acute lymphadenitis 396
 cat-scratch disease 399–400
 granulomatous
 lymphadenitis 397–9
 reactive hyperplasia 400–2
 silicone-associated
 lymphadenitis 402
macrophages 86
malakoplakia, renal 575–7
 clear cell RCC *vs.* 557
 xanthogranulomatous
 pyelonephritis *vs.* 574
malaria 467
male breast 380–2
malignancies of unknown
 primary (MUP) site
 620–41
clinical patterns of metastases
 634–40
 adrenal glands 637
 breast 638
 common sites of metastasis
 634
 cytologic features 637
 kidney 639
 large bones 636
 liver 636–7
 lung 636
 lymph nodes 635–6
 most common primaries
 635
 orbit 640
 pancreas 639
 salivary glands 637–8
 small bones 639–40
 spindle cell malignancies in
 bone 636
 spleen 640
 thyroid 638
 tumor-to-tumor metastasis
 640
 unusual sites of metastasis
 635
cytomorphology 622–30
 clear cell 627–8
 high grade columnar/
 ductal adenocarcinoma
 624–5
 large cell/polygonal,
 cohesive 629
 large cell/polygonal,
 noncohesive 629–30
 low grade columnar/ductal
 adenocarcinoma 624
 microacinar/microfollicular
 complexes 624–9
 miscellaneous 631–2
 morphologic patterns of
 metastatic malignancies
 622–4
 mucinous neoplasms 625
 oncocytic/granular 627
 papillary configuration
 625–6
 pleomorphic/giant cell
 628–9
 small cell, cohesive 626
 small cell, noncohesive
 626–7
 spindle cell 629–30
diagnosis 632
fine-needle aspiration in
 620–1
histologic subtypes 621–2
 adenocarcinoma 621
 lymphoma 622
 melanoma 622
 sarcoma 622
 squamous cell carcinoma
 621–2
immunohistochemistry 632–3
 differential cytokeratins
 632–3
 epithelial membrane
 antigen expression 633
 estrogen receptor 633
 immunohistochemistry
 approach to MUP 632
malignant melanoma 622
metastasis sites (*see specific
sites*)
miscellaneous cytologic
 features 631–2
 granulomas, malignancies
 associated with 631–2
 intracytoplasmic hyaline
 globules 631
 intranuclear inclusions 631
 molecular testing 633–4
malignant fibrous histiocytoma
 529–30
malignant lymphoma, lung
 435–7
malignant melanoma
 intraocular cytology 193–4
 on Pap smear 28
malignant mesenchymal tumors
 (sarcomas) 376–7
malignant mesothelioma (MM)
 92–7, 439–41
 clinical features 92–4
 histology 94
 immunostains 94, 96
 markers
 negative 95–6
 positive 94–5
 sarcomatoid 441
 solitary fibrous tumor *vs.*
 441
malignant mesothelioma, pleura
 439–41
malignant mixed Mullerian
 tumor (MMMT)
 (carcinosarcoma), of
 Mullerian origin 23–4,
 106
malignant neoplasms
 exfoliative pulmonary
 cytology 62–74
 ADC-LP/AIS 68–9
 hematopoietic malignancies
 73–4
 invasive bronchogenic
 adenocarcinoma 65–8
 large cell carcinoma 72–3
 neuroendocrine tumors
 69–72
 squamous cell carcinoma
 63–5
liver 472–6
 cholangiocarcinoma 474–5
 hepatoblastoma 475–6
 hepatocellular carcinoma
 472–4
salivary glands 321–33
 acinic cell carcinoma 324–5

Index

- malignant neoplasms (*cont.*)
 adenoid cystic carcinoma 322–4
 Ca exPA 329–30
 epithelial-myoepithelial carcinoma 327–8
 lymphoma 331–2
 mucoepidermoid carcinoma 321–2
 polymorphous adenocarcinoma 326–7
 salivary duct carcinoma 330–1
 secondary malignancies 332–3
 secretory carcinoma 325–6
 squamous cell carcinoma 328–9
- malignant nodules, thyroid gland 267–75
 lymphoma 274–5
 medullary thyroid carcinoma 270–2
 metastatic tumors 275
 papillary thyroid carcinoma 267–70
 poorly differentiated thyroid carcinoma 272–3
 suspicious for malignancy 265–7
 undifferentiated (anaplastic) thyroid carcinoma 273–4
- malignant peripheral nerve sheath tumor (MPNST) 454–5, 526–7
 benign peripheral nerve sheath tumor *vs.* 453
 schwannoma *vs.* 298
 synovial sarcoma *vs.* 512
- malignant tumors, body cavity fluids 112–16
 germ cell tumors 112–14
 melanoma 115
 renal cell carcinoma 115
 sarcoma 112
 urothelial cell carcinoma 115–16
 Wilms tumor (nephroblastoma) 116
- MALT, chronic sclerosing sialadenitis *vs.* 308
 MALT lymphoma, benign lymphoepithelial cyst *vs.* 310
 MALToma 144
 mammaglobin 67, 98–9, 100, 103–4, 325, 418, 481, 634
 mammary analog secretory carcinoma (MASC) 325–6
 mantle cell lymphoma 405–7
 MAP-2 133, 141, 147
 marginal zone lymphoma 407
 MART-1 293, 332
 MASC *see* mammary analog secretory carcinoma
- mastitis 345–6
 lymphoma *vs.* 378
 mediastinal nonseminomatous germ cell tumor 452–3
 mediastinal seminoma 451–2
 mediastinal teratoma 450–1
 mediastinal tumors 443–57
 classic Hodgkin lymphoma 449–50
 cyst 443
 ganglioneuroblastoma 456–7
 ganglioneuroma 456
 germ cell tumors 452–3
 Hodgkin's lymphoma 449–50
 mediastinal nonseminomatous germ cell tumor 452–3
 mediastinal seminoma 451–2
 mediastinal teratoma 450–1
 neuroblastoma 456–7
 paraganglioma 455–6
 peripheral nerve sheath tumor
 benign 453–4
 malignant 454–5
 peripheral neuroectodermal tumor 457
 primary large B-cell lymphoma 447–8
 reactive spindle cell lesions 454
 rhabdomyosarcoma 457
 sarcomatoid carcinoma, MPNST *vs.* 455
 seminoma 451–2
 solitary fibrous tumor 454
 spindle cell melanoma, MPNST *vs.* 455
 spindle cell sarcoma, MPNST *vs.* 455
 T-cell lymphoblastic lymphoma 448–9
 teratoma 450–1
 thymic carcinoma 445–6
 thymic cysts 443–4
 thymic neuroendocrine carcinoma 446–7
 thymoma 443–5
- medium/large cell lymphomas 408–12
 anaplastic large cell lymphoma 410–11
 Burkitt lymphoma 411–12
 diffuse large B-cell lymphoma 408–9
 peripheral T-cell lymphoma, NOS 410
 precursor T and B-cell lymphoblastic lymphomas 409–10
 T-cell lymphoma, peripheral NOS 410
- medullary breast carcinoma 366–7
 medullary thyroid carcinoma 270–2
 giant cell rich variant 271
- oncocytic variant 271
 poorly differentiated thyroid carcinoma *vs.* 272
 spindle cell variant 271
 suspicious for 265–7
- medulloblastoma 186–7, 237–8
 Melan A 28, 115, 194, 195, 198, 419, 438, 479, 499, 572, 579, 585, 633
- melanoma
 adenocarcinoma *vs.* 133
 angiosarcoma *vs.* 542
 body cavity fluids 115
 breast 379–80
 esophagus 133
 hepatocellular carcinoma *vs.* 474
 intraocular 193–4
 large cell undifferentiated carcinoma *vs.* 431
 malignant 622
 Merkel cell carcinoma *vs.* 293
 metastatic 239, 332, 416–17, 438–9, 480, 499, 568
 metastatic malignant neoplasms, liver 481
 pheochromocytoma *vs.* 586
 soft tissue and bone
 clear cell sarcoma *vs.* 516
 epithelioid sarcoma *vs.* 515
 Langerhans' cell histiocytosis *vs.* 518
 spindle cell 455
 of unknown origin 622, 623
- meningioma 227–8
 meningitis
 bacterial 180–1, 206–7
 cryptococcal 207–8
 fungal 181–2, 207–8
 leukemic/lymphomatous 183–4
 Mollaret 211
 viral 181, 208–9
- Merkel cell carcinoma 292–3
 mesenchymal tumors
 breast 373–5
 fibromatosis 373
 granular cell tumor 376–7
 lipoma 374
 myofibroblastoma 374–5
 spindle cell lipoma 374
 esophagus 134–5
- mesothelial cells 83–6
 quiescent 83–5
 reactive 85–6
 mesothelial hyperplasia 440
 mesothelin 95
 mesothelioma *see* malignant mesothelioma (MM)
 metanephric adenoma
 papillary renal cell carcinoma *vs.* 558
 small round cell tumors *vs.* 581
- metaplastic carcinoma 367–8
 adenocarcinoma *vs.* 368
- fibromatosis *vs.* 373
 phyllodes tumor *vs.* 372
 metastases, clinical patterns of 634–40
 adrenal glands 637
 breast 638
 common sites of metastasis 634
 cytologic features 637
 kidney 639
 large bones 636
 liver 636–7
 lung 636
 lymph nodes 635–6
 most common primaries 635
 orbit 640
 pancreas 639
 salivary glands 637–8
 small bones 639–40
 spindle cell malignancies in bone 636
 spleen 640
 thyroid 638
 tumor-to-tumor metastasis 640
 unusual sites of metastasis 635
- metastatic adenocarcinoma 428, 440
 metastatic carcinoma 97–103
 adenocarcinoma 99–100, 428, 440
 adrenal glands 587, 637
 breast 25–6, 97–9, 239, 481
 central nervous system 238–42
 clinical patterns of metastases 634–40
 colonic adenocarcinoma 26–7, 108, 479
 gastric 107–10, 138–40, 481
 intraocular cytology 198
 kidney 569, 571
 liver 478–80, 636–7
 lung 99, 427–8, 636
 ovarian 600–5, 609
 pancreas 499, 639
 renal 552–67
 small cell carcinoma 102–3
 squamous cell carcinoma 101–2
 thyroid gland 270–2, 275
 of unknown primary site (*see* malignancies of unknown primary (MUP) site)
- metastatic disease
 to breast 379–80
 to lymph nodes 414–19
- metastatic malignancies
 lung 438–9
 morphologic patterns of 622–4
 pleura 442–3
- metastatic neoplasms
 central nervous system 238–42

- CSF findings 239–40
FNB findings 241–2
liver 478
 breast carcinoma 481
 colonic adenocarcinoma 479
 gastric adenocarcinoma 481
 melanoma 481
 metastasis, general 478–9
 neuroendocrine tumor 479
 prostate adenocarcinoma 481
 sarcoma 481
 squamous cell carcinoma 480–1
metastatic tumors
 adrenal gland 587
 ovary 609
 pancreas 499
 thyroid gland 275
MIB-1 202, 415
Michaelis-Guttman bodies 169, 575, 576
microacinar/microfollicular complexes 624–9
microglandular adenosis 351
Mikulicz's disease, benign lymphoepithelial cyst vs. 310
MILAN III (mucocele) 312–13
Milan system 304–5
mitomycin, urine changes 170
mixed epithelial stromal tumor (MEST) 554
 congenital mesoblastic nephroma vs. 554
 cystic partially differentiated nephroblastoma vs. 554
 leiomyoma vs. 554
 renal sarcoma vs. 554
 sarcomatoid renal cell carcinoma vs. 554
mixed hepatocellular/cholangiocarcinoma 473
MOC31 67, 110
molecular studies, in non-Hodgkin lymphomas 414–19
molecular testing 633–4
 central nervous system 203–4
 thyroid gland, atypia of undetermined significance/follicular lesion of undetermined significance 261
Mollaret meningitis 211
monomorphic adenoma 316–18
MPNST *see* malignant peripheral nerve sheath tumor (MPNST)
MSA 380
MUC1 494
MUC2 28, 105, 107–10, 492, 609
MUC5AC 105, 107–10, 494
MUC5B 110
mucicarmine 46, 56–7, 107–8, 129, 163, 173, 182, 191, 208, 240, 305, 365, 474, 576
mucin-rich adenocarcinoma, chordoma vs. 539
mucinous (colloid) carcinoma 365–6
mucinous cystic neoplasm, pancreas 491
mucins 332
mucocele (MILAN III) 312–13
mucoepidermoid carcinoma
 lung 435
 metastatic 435
 salivary gland 321–2
 benign lymphoepithelial cyst vs. 310
 benign mixed tumor/pleomorphic adenoma vs. 316
 secondary malignancies vs. 332
 secretory carcinoma vs. 326
 squamous cell carcinoma vs. 329
 Warthin's tumor vs. 320
mucosa-associated lymphoid tissue *see* MALToma
mucus retention cyst 313
Mullerian origin tumors 103–6
 cervical carcinoma 106
 endometrioid adenocarcinoma 105–6
 MADC 104–5
 malignant mixed Mullerian tumor 106
 ovarian borderline serous papillary tumor 104
 ovarian carcinoma 103–4
 uterine carcinoma 105
multinucleated giant cells 46–7
multiple sclerosis (demyelinating disease) 214–15
muscle specific antigen *see* MSA
MYB immunostain 323
mycobacterial infection
 duodenum 145
 respiratory 55
myelolipoma 508, 588, 589
myeloperoxidase 415
myoepithelial carcinoma 318
myoepithelial sialadenitis 311–12
myoepithelioma 318
myofibroblastoma 374–5
myogenin 634
myositis ossificans 519–20
myositis, proliferative 518–19, 520
myxoid chondrosarcoma 510
myxoid liposarcoma 509, 510
 high-grade 509
 intramuscular myxoma vs. 534
myxoid malignant fibrous histiocytoma 510
myxoma 510, 519
 intramuscular 533–4
 ganglion cyst vs. 534
 myxoid liposarcoma vs. 510, 534
 pseudosarcomatous spindle cell lesions vs. 519
myxopapillary ependymoma 226–7
N-cadherin 96
napsin A 100, 430, 432, 499, 634
nasopharyngeal carcinoma 291–2
necrotizing lymphadenitis 257
 acute thyroiditis vs. 257
needle biopsy *see* fine-needle aspiration (FNA)
Neisseria gonorrhoea, in Pap smear 10
neoplasm
 solid pseudopapillary, pancreas 494–5
 thyroid gland 262–5
 follicular neoplasm 262–3
 NIFTP 262–3
 oncocytic (Hürthle cell) neoplasms 263–5
neoplastic mucinous cysts 491–2
 IPMN 491–2
 mucinous cystic neoplasm 491
 pancreas 491–2
nephroblastoma (Wilms tumor) 116, 577–8
 cystic partially differentiated 553
 kidney 577–8
 small round cell tumors vs. 581
nephrogenic adenoma, bladder adenocarcinoma vs. 174
nephroma
 congenital mesoblastic, mixed epithelial stromal tumor vs. 554
 cystic 553
neurilemmoma *see* schwannoma
neuroblastic tumors 588–9
neuroblastoma 456–7
 mediastinal 456–7
 precursor T-cell lymphoblastic lymphoma vs. 444, 445
 small round cell tumors vs. 581
neuroendocrine tumors 69–72
 cervix 20–1
 duodenum 147
 metastatic 417, 418
 pancreas 497–9
 respiratory system 69–72
 large cell 71
 small cell 71
 typical/atypical carcinoid 69–71
stomach 140–2
thymus 446–7
well differentiated NET and small cell carcinoma 479
neurofibroma 453–4
neurofibrosarcoma, leiomyosarcoma vs. 528
neuron specific enolase 197, 380
neutrophils, respiratory system 47
nipple discharge 342
NKX3.1 634
nodular fasciitis 296–7
 breast, myofibroblastoma vs. 375
 soft tissue and bone 518–19, 520, 522
 fibromatosis vs. 519
 myositis ossificans vs. 520
nodular goiter, parathyroid adenoma vs. 284
nodules, cirrhotic 471–2
non-Hodgkin's lymphoma (NHL) 110, 292, 404
 immunohistochemistry 413–14
 lymphoid markers 415
 molecular studies 414–19
 nasopharyngeal carcinoma vs. 292
 neuroblastoma/ganglioneuroblastoma vs. 457
non-keratinizing squamous cell carcinoma 19
noninfectious inflammatory conditions, urinary cytology 166
noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) 262–3
nonneoplastic conditions
 kidney 548–50
 lymph nodes 396–402
 salivary glands 305–13
nonproliferative breast disease 349–55
 breast cysts 349–50
 collagenous spherulosis 350–1
 microglandular adenosis 351
 pregnancy and lactational changes 353–4
 sclerosing adenosis 352
 treatment induced changes 354–5
 tubular adenoma 352–3
OCT3/4 445, 451, 452, 453, 606, 612, 613
Oil Red O 189
oligodendroglioma 234
oncocytic carcinoma 319
oncocytic cystadenoma 326
oncocytic (Hürthle cell) neoplasms 263–5

Index

- oncocytoma 319–20, 570, 571–2
 chromophobe renal cell carcinoma vs. 562
 clear cell renal cell carcinoma vs. 575 555
 kidney 548, 571–2
 chromophobe RCC vs. 571
 clear cell RCC vs. 571
 salivary gland 319–20
 benign mixed tumor/pleomorphic adenoma vs. 317
 MASC vs. 326
 Warthin's tumor vs. 320
 oncocytosis 319
 orbit metastases 640
 orchitis 610
 osteoclast-rich osteosarcoma, chondroblastoma vs. 533
 osteomyelitis, Langerhans' cell histiocytosis vs. 518
 osteosarcoma 539–40
 chondroblastic, chordoma vs. 538
 chondrosarcoma vs. 540
 giant cell-rich, giant cell tumor of bone vs. 531
 osteoclast-rich, chondroblastoma vs. 533
 pleomorphic sarcoma vs. 540
 ovarian tumors 597–609
 adenocarcinoma
 metastatic 25
 mucinous 104–5
 borderline serous papillary tumor, of Mullerian origin 104
 Brenner tumor 603–4
 carcinoma 600–5
 clear cell 605
 endometrioid 604–5
 mucinous cystadenoma 602–3
 of Mullerian origin 103–4
 serous cystadenoma 600–2
 serous, from either ovary 24–5
 choriocarcinoma 615
 clear cell carcinoma 605
 metastatic 605
 corpus luteum cyst 598–9
 endometriotic cyst vs. 599
 follicular cyst vs. 599
 cortical inclusion cyst, serous cystadenoma/carcinoma vs. 602
 cystadenofibroma, serous cystadenoma/carcinoma vs. 602
 dysgerminoma 606
 embryonal carcinoma 615
 endometrioid carcinoma 604–5
 endometriotic cyst 599–600
 corpus luteum cyst vs. 600
 fibroma/thecoma 608
 follicular cyst 597–8
 corpus luteum cyst vs. 599
 granulosa cell tumor 606–8
 Brenner tumor vs. 603–4
 MADC 104–5
 metastatic tumors 609
 mucinous cystadenoma/carcinoma vs. 602–3
 mucinous cystadenoma/carcinoma 602–3
 serous cystadenoma/carcinoma 600–2
 teratoma 615
 yolk sac tumor 614–15
 P16 18, 21, 27, 101
 P16INK 21, 22
 P16INK4 2
 P40 101
 P53 106, 288, 372, 585
 P63 20, 41, 101, 171, 318, 322, 328, 352, 430, 432, 433, 566
 P80 437
 P501S 634
 Paget's disease of the vulva, on Pap smear 27–8
 pancreatic pseudocyst 489
 lymphoepithelial cyst vs. 489
 serous cystadenoma vs. 490
 pancreatic tumors 485–99
 acinar cell carcinoma 496–7
 benign acinar cells vs. 497
 pancreatoblastoma vs. 497
 solid-pseudopapillary neoplasm vs. 497
 adenocarcinoma 109–10
 autoimmune pancreatitis vs. 488
 chronic pancreatitis vs. 487
 colloid 492
 ductal 492–4
 mucinous 491–2
 well differentiated 129–30, 492
 carcinoma
 adenosquamous 492
 signet ring 494
 undifferentiated 493
 dermoid cyst,
 lymphoepithelial cyst vs. 489
 endocrine neoplasm 494–5
 acinar cell carcinoma vs. 495
 solid pseudopapillary neoplasm 494–5
 solid-pseudopapillary neoplasm vs. 494–5
 heterotopic, carcinoid tumor vs. 142
 lymphoepithelial cyst 489
 pancreatic pseudocyst vs. 489
 lymphoepithelial cyst 489
 metastases, clinical patterns of 639
 metastatic tumors 499, 639
 mucinous cystic neoplasms 491–2
 IPMN 489, 491–2
 mucinous cystic neoplasm 491
 pancreatic pseudocyst vs. 489
 mucinous neoplasms, serous cystadenoma vs. 489
 neoplastic mucinous cysts 491–2
 IPMN 491–2
 mucinous cystic neoplasm 491
 pancreatitis 485–8
 acute pancreatitis 485–6
 autoimmune pancreatitis 487–8
 chronic pancreatitis 486–7
 pancreatoblastoma 495–6
 pseudocyst 488–9
 reporting terminology 485
 serous cystadenoma 489–91
 solid pseudopapillary neoplasm 494–5
 acinar cell carcinoma vs. 495
 endocrine neoplasm vs. 495
 tumors
 metastatic 499, 639
 neuroendocrine 497–9
 pancreatitis 485–8
 acute pancreatitis 485–6
 autoimmune pancreatitis 487–8
 chronic pancreatitis 486–7
 effusions 91–2
 pancreatoblastoma 495–6
 pankeratin 426, 446
 PAP 381
 PAP smear 1–30
 The Bethesda system (TBS) 1
 adenocarcinoma
 breast 25–6
 colon 26–7
 endocervical 21–2
 endometrial 22–3
 gastric 26
 in-situ of endocervix 21
 adequacy 1–2
 anal Pap smear 29–30
 atypical squamous cells
 high grade squamous intraepithelial lesion 14–15
 of undetermined significance 14
 benign findings 2–13
 Arias–Stella change of pregnancy 3–4
 endometrial cells 2–3
 relative changes associated with inflammation 4–6
 carcinosarcoma (malignant mixed Mullerian tumor) 23–4
 cervical cancer screening 2
 contaminants in Pap smear 11–13
Alternaria alternata 11
 astersclereids 11–12
 carpet beetle larval parts 13
 plant matter 12
 pollen 13
 trichomes 12–13
 endometrial cells 2–3
 extrauterine/metastatic malignancies 24–9
 breast adenocarcinoma 25–6
 colon adenocarcinoma 26–7
 gastric adenocarcinoma 26
 lymphoma 29
 malignant melanoma 28
 Paget's disease of the vulva 27–8
 serous carcinoma from either ovary or fallopian tube 24–5
 urothelial cell carcinoma 27
 high-grade sarcomas 24
 high-grade squamous intraepithelial lesions 16
 involving endocervical glands 16
 history 1
 HPV test 2
 keratinizing squamous cell carcinoma 18–19
 low-grade squamous intraepithelial lesions 15–16
 microorganisms in Pap smear 6–11
Actinomyces 9
Candida albicans 6
Chlamydia trachomatis 10–11
 cytomegalovirus 7–8
Gardnerella vaginalis 9
 herpes simplex virus 6–7
Leptothrix 8–9
Neisseria gonorrhoea 10
 pubic louse or “crab” 11
Schistosoma haematobium 9–10
Trichomonas vaginalis 8
 neuroendocrine carcinoma of cervix 20–1
 nonkeratinizing squamous cell carcinoma 19
 papillary squamo-transitional cell carcinoma of cervix 19–20
 reporting 2
 sample preparations 1
Schistosoma haematobium 9–10
 screening guidelines 1
 small cell carcinoma 20–1

- papillary adenoma, papillary renal cell carcinoma *vs.* 557
- papillary carcinoma
breast 356–8
renal cell 557–61
- papillary cystadenocarcinoma epithelial-myoepithelial carcinoma *vs.* 328
polymorphous low grade adenocarcinoma *vs.* 327
- papillary renal cell carcinoma 557–61
collecting duct renal cell carcinoma *vs.* 564
metanephric adenoma *vs.* 558
mucinous tubular/spindle cell carcinoma *vs.* 558–9
papillary adenoma *vs.* 557
thyroid-like follicular renal carcinoma *vs.* 561
urothelial carcinoma *vs.* 558
- papillary squamo-transitional cell carcinoma of cervix 19–20
- papillary thyroid carcinoma (PTC) 267–70
columnar cell variant 269
cystic variant 269
follicular thyroid neoplasm *vs.* 270
follicular variant 269
Hürthle cell neoplasm *vs.* 264
hyalinizing trabecular adenoma 270
metastasis 289–90
oncocytic (Hürthle cell) 269
parathyroid adenoma *vs.* 285
poorly differentiated thyroid carcinoma *vs.* 273
sclerosing 269
suspicious for 265–7
tall cell variant 269
Warthin-like variant 269
- papilloma 356–8
Paracoccidioides brasiliensis 58
paraganglioma 293–4
carotid body tumor 293–4
mediastinum 455–6
thymic neuroendocrine carcinoma *vs.* 446
- parakeratosis 5
- parasitic infections
central nervous system 211–13
cysticercosis 213
toxoplasmosis 211–13
cerebrospinal fluid 182–3
effusions 90
urinary tract 169
see also specific parasitic infections
- parathyroid gland tumors 282–5
adenoma 283–4
branchial cleft cyst 285–7
carcinoma 284–5
cystic papillary thyroid carcinoma 253
cysts 282–3
hyperplasia, parathyroid adenoma *vs.* 284
Merkel cell carcinoma 292–3
nasopharyngeal carcinoma 291–2
paraganglioma (*see* paraganglioma)
pilomatrixoma 295–6
schwannoma 297–8
secondary tumors 285
thymic neuroendocrine carcinoma *vs.* 446
thyroglossal duct cyst 287–8
- Paris System 160–2
diagnostic categories and criteria 160–2
introduction 160
PAX2 103, 548, 555, 557, 558, 559, 562, 564
PAX5 404, 447, 448
PAX8 103, 104, 262, 263, 272, 274, 276, 325, 333, 418, 419, 438, 443, 444, 479, 498, 548, 555, 557, 558, 559, 561, 562, 564, 579, 625, 637, 638
- Penicillium marneffe* 467
- peptic ulcer disease
duodenum 145
gastric polyps *vs.* 138
stomach 136–7
- periodic acid–Schiff 46, 84, 191
- peripheral nerve sheath tumor fibromatosis *vs.* 522
fibrosarcoma *vs.* 527
malignant 454–5
mediastinum benign 453–4
schwannoma *vs.* 522
soft tissue and bone, malignant 512, 526–7
solitary fibrous tumor *vs.* 440, 527
see also neurofibroma; schwannoma
- peripheral neuroectodermal tumor (PNET), neuroblastoma/ganglioneuroblastoma *vs.* 457
- peripheral T-cell lymphoma, NOS 410
- phacolytic glaucoma 189–90
- pheochromocytoma 586–7
adrenal cortical carcinoma *vs.* 586, 587
melanoma *vs.* 586–7
metastatic carcinoma *vs.* 586
- phosphotungstic acid–hematoxylin 319
- phyllodes tumor 371–3, 375
fibroadenoma *vs.* 372
metaplastic carcinoma *vs.* 372–3
myofibroblastoma *vs.* 375
- phytoestrogen-induced Arias–Stella reaction 3
- pilocytic astrocytoma 223–4
- pilomatrixoma (calcifying epithelioma of Malherbe) 295–6
- pineal tumors 236–8
medulloblastoma 237–8
pineoblastoma 236–7
pineocytoma 236
- pineoblastoma 236–7
pineocytoma 236
- placenta-like alkaline phosphatase (PLAP) 450, 614
- PLAG-1 315, 317
- plant matter, in Pap smear 12
- PLAP 450, 614
- plasmacytoma, pancreatic endocrine neoplasm *vs.* 499
- pleomorphic adenoma (PA) 313–16
adenoid cystic carcinoma *vs.* 315
basal cell adenoma *vs.* 315
bronchial salivary gland tissue 425
carcinoma from 326, 339–40
316, 329–30
cellular 317, 328
lung, adenoid cystic carcinoma *vs.* 434
MASC *vs.* 325
mucoepidermoid carcinoma *vs.* 316
nodular fasciitis *vs.* 297
oncocytoma *vs.* 316
polymorphous adenocarcinoma *vs.* 315–16
salivary gland 313–16, 317
squamous cell carcinoma *vs.* 329
with squamous metaplasia 322
- pleomorphic/giant cell tumors hepatocellular carcinoma 473
of unknown origin 628
- pleomorphic lipoma 508
- pleomorphic liposarcoma 509–10
pleomorphic lipoma *vs.* 510
- pleomorphic rhabdomyosarcoma 528–30
leiomyosarcoma *vs.* 529
- pleomorphic sarcoma, osteosarcoma *vs.* 540
- pleural tumors 439–43
adenocarcinoma, mesothelioma *vs.* 440
malignant mesothelioma 439–41
mesothelioma *vs.* 440
metastatic malignancy 442–3
sarcomatoid carcinoma, mesothelioma *vs.* 440
- solitary fibrous tumor 441–2
spindle cell sarcoma, mesothelioma *vs.* 440
- Pneumocystis jiroveci* (formerly *Pneumocystis carinii*), in respiratory infections 58–9
- pneumocytes
type I 43
type II 43
hyperplasia 43–5
- pneumonia
aspiration 54
bacterial 55
- podoplanin 95
- pollen, in Pap smear 13
- polymerase chain reaction 395, 412
- polymorphous adenocarcinoma 326–7
- polyoma virus 166–7
- polyps, stomach 138
- poorly differentiated
adenocarcinoma (PDD) of lung 430
- poorly differentiated neuroendocrine carcinoma, on Pap smear 20–1
- poorly differentiated thyroid carcinoma (insular/trabecular/solid carcinoma) 272–3
- precursor T and B-cell lymphoblastic lymphomas 409–10, 448
mediastinal B-cell lymphoma *vs.* 449
thymoma *vs.* 448
- pregnancy
Arias–Stella change 3–4
breast changes 351, 354
lactational changes 353–4
- primary effusion lymphoma (PEL) 111–12
- primary intraocular malignant lymphoma 194–6
- primary mediastinal large B-cell lymphoma 447–8
- primary neoplasms, central nervous system (CNS)
malignant 218–23
anaplastic astrocytoma 219–21
glioblastoma multiforme 221–3
low-grade astrocytoma 218–19
- miscellaneous 225–31
atypical teratoid/rhabdoid tumors 229–30
choroid plexus papilloma/carcinoma 228
ependymoma 225–6
germ cell tumors 230–1

Index

- primary neoplasms, central nervous system (CNS) (*cont.*)
 meningioma 227–8
 myxopapillary ependymoma 226–7
 primitive neuroectodermal tumor (PNET) 534–5
see also Ewing's sarcoma (ES)/primitive neuroectodermal tumor (PNET)
 ProExC 15
 progesterone receptor (PR) 98, 360, 376, 382, 495, 554, 572
 progressive multifocal leukoencephalopathy (PML) 209–10
 proliferative breast disease 355–6
 fibroadenoma *vs.* 370–1
 infiltrating ductal carcinoma 360–3
 tubular carcinoma *vs.* 363–5
 without/with atypia 355–6
 proliferative fasciitis 518–19, 520
 proliferative myositis, soft tissue and bone 518–19, 520
 prostate acid phosphatase 634
 prostate gland adenocarcinoma 172
 adrenal cortical adenoma/hyperplasia *vs.* 584
 adrenal cortical carcinoma *vs.* 584
 carcinoma, metastatic 481
 prostate specific antigen *see* PSA
 prostatic acid phosphatase *see* PAP
 Prussian blue 188
 PSA 381, 418, 585, 621, 624, 634
 psammoma bodies, in exfoliative pulmonary cytology 49
 pseudo-orangeophilia 39
 pseudo-tumoral macrophage-rich lesions 213–14
 pseudocyst, pancreas 488–9
 pseudomyxoma peritonei 110
 pseudosarcomatous spindle cell lesions 518–19
 PSMA 634
 pubic (crab) louse 11
 pulmonary alveolar microlithiasis 49–50
 pulmonary alveolar proteinosis 51–2
 pulmonary hamartoma 425–6
 pulmonary infarct/embolism 53
 pulmonary (alveolar) macrophages 45
 hemosiderin-laden 45–6
 pulmonary native cells, from normal to reactive 38–47
 alveolar lining cells 43–5
 bronchial cell hyperplasia (Creola bodies) 42–3
 cells within alveolar spaces 45–6
 goblet cell hyperplasia 41
 inflammatory cells 47
 multinucleated giant cells 46–7
 reactive and reparative bronchial cell changes 40–1
 reserve cell hyperplasia 42–3
 squamous cells 38–9
 tracheobronchial lining cells 39–40
 pulmonary-related diseases 51–3
 pulmonary alveolar proteinosis 51–2
 pulmonary infarct/embolism 53
 sarcoidosis 52–3
 pyelonephritis, xanthogranulomatous, clear cell renal cell carcinoma *vs.* 574
 pyogenic abscess 466
 quiescent mesothelial cells 83–5
 radiation therapy, effects of
 breast 354–5
 esophagitis 126–7
 respiratory system 61–2
 urinary cytology 170, 171
 Rathke's cleft cyst 216
 RCC *see* renal cell carcinoma
 RCCMa 548–9, 555, 556, 557, 558, 559, 562, 564, 566, 571, 579
 reactive and reparative bronchial cell changes 40–1
 reactive body cavity fluids 83
 reactive changes in PAP smears 4–6
 reactive hyperplasia 400–2
 reactive mesothelial cells 85–6
 Reed–Sternberg cells 404
 renal abscess 573–4
 renal cell antigen 634
 renal cell carcinoma (RCC) 115, 548, 552
 adrenal cortical carcinoma *vs.* 585
 body cavity fluids 115
 chromophobe 561–3
 clear cell 554–7
 angiomyolipoma *vs.* 557
 oncocytoma *vs.* 556, 591
 renal metastatic carcinoma *vs.* 588, 589
 collecting duct 563–4
 cyst *vs.* 552
 cystic 552
 cystic nephroma *vs.* 553
 hepatocellular carcinoma *vs.* 474
 metastatic 351
 acinic cell carcinoma *vs.* 326
 epithelial-myoepithelial carcinoma *vs.* 328
 papillary 557–61
 renal pelvis urothelial carcinoma *vs.* 566
 sarcomatoid 564–6
 angiomyolipoma *vs.* 557, 572
 urothelial carcinoma *vs.* 178
 renal cell carcinoma marker *see* RCCMa
 renal hybrid oncocytic tumor, chromophobe renal cell carcinoma *vs.* 563
 renal malakoplakia 575–7
 renal pelvis urothelial carcinoma (UC) 566–7
 collecting duct renal cell carcinoma *vs.* 566
 RCC *vs.* 566
 sarcomatoid renal cell carcinoma *vs.* 566
 reserve cell hyperplasia 42–3
 respiratory infections 54–60
Actinomyces and *Candida* 55
 bacterial pneumonia 55
 fungal infections 55–8
 mycobacterial infection 55
Pneumocystis jiroveci (formerly *Pneumocystis carinii*) 58–9
 viral infections 59–60
 respiratory system *see* exfoliative pulmonary cytology;
specific parts
 reticulin 471, 473
 retinoblastoma 196–7
 rhabdoid tumor 581–2
 extrarenal 516–17
 small round cell tumors *vs.* 582
 rhabdomyoma
 alveolar soft part sarcoma *vs.* 514
 granular cell tumor *vs.* 514
 rhabdomyosarcoma 535–7
 embryonal and alveolar subtypes 535–7
 alveolar soft part sarcoma *vs.* 514
 lymphoma *vs.* 537
 rhabdomyosarcoma *vs.* 537
 Ewing's sarcoma *vs.* 535
 neuroblastoma/
 ganglioneuroblastoma *vs.* 457
 pleomorphic 528–9
 leiomyosarcoma *vs.* 529
 small round cell tumors *vs.* 581
 soft tissue and bone
 alveolar 513–14
 granular cell tumor *vs.* 513
 pleomorphic 528–9
 rheumatoid pleuritis, effusions 88
 Riedel's thyroiditis 258
 Rosai–Dorfman disease, acute lymphadenitis *vs.* 396
 round cell liposarcoma *see* high-grade myxoid liposarcoma
 round cell tumors
 desmoplastic small round cell tumor 581
 liposarcoma 508–11
 pilomatixoma *vs.* 295
 small round blue cell tumors 231–4
 small round cell tumors of kidney 578–81
 S-100 81, 197, 218, 275, 293, 297, 298, 315, 318, 328, 332, 368, 373, 375–7, 379, 380, 419, 507, 508, 510–16, 518, 522, 523, 525–8, 530, 532–5, 539, 540, 572, 578, 580, 584–7, 589, 627, 629, 633
 salivary duct cyst, benign lymphoepithelial cyst *vs.* 330–1
 salivary gland tumors 304–33
 acinic cell carcinoma 324–5
 MASC *vs.* 325
 oncocytoma *vs.* 319
 sialadenosis *vs.* 325
 adenoid cystic carcinoma 322–4
 basal cell adenoma *vs.* 315
 epithelial-myoepithelial carcinoma *vs.* 327
 polymorphous adenocarcinoma *vs.* 327
 analog tumors 75
 ancillary studies, general principles 305
 basal cell adenocarcinoma, basal cell adenoma *vs.* 317
 basal cell adenoma 316–18
 adenoid cystic carcinoma *vs.* 323
 basal cell adenocarcinoma *vs.* 317
 benign mixed tumor/
 pleomorphic adenoma *vs.* 315
 benign lymphoepithelial cyst 309–11
 Warthin's tumor *vs.* 321
 benign mixed tumor 313–16
 Ca-ex-PA *vs.* 330
 benign neoplasms 313–21
 basal cell adenoma 316–18
 benign mixed tumor/
 pleomorphic adenoma 313–16

- myoepithelioma 318
oncocytoma 319–20
Warthin's tumor 320–1
- Ca-ex-PA 329–30
benign mixed tumor/
pleomorphic adenoma
vs. 330
- epithelial-myoepithelial
carcinoma 327
adenoid cystic carcinoma
vs. 323
polymorphous
adenocarcinoma vs. 327
- intraparotid lymph node
hyperplasia 309, 332
- Kuttner's tumor 308–9
- low grade mucoepidermoid
carcinoma 310, 316, 320,
322, 326
- lymphoma 331–2
- malignant neoplasms 321–33
acinic cell carcinoma 324–5
adenoid cystic carcinoma
322–4
Ca exPA 329–30
epithelial-myoepithelial
carcinoma 327–8
lymphoma 331–2
mucoepidermoid
carcinoma 321–2
polymorphous
adenocarcinoma 326–7
salivary duct carcinoma
330–1
secondary malignancies
332–3
secretory carcinoma 325–6
squamous cell carcinoma
328–9
- metastatic tumors 637–8
malignant mixed tumor
vs. 330
- MILAN III 312–13
Milan system 304–5
- monomorphic adenoma,
benign mixed tumor/
pleomorphic adenoma
vs. 315–16
- mucoepidermoid carcinoma
321–2
high grade 322, 329, 330, 332
low grade 316
MASC vs. 325
secondary malignancies
vs. 332
squamous cell carcinoma
vs. 329
Warthin's tumor vs. 320
- mucus retention cyst,
mucoepidermoid
carcinoma vs. 322
- myoepithelial carcinoma,
myoepithelioma vs. 318
- myoepithelioma 318
- nonneoplastic conditions
305–13
- acute sialadenitis 307–8
benign intraparotid lymph
node 312
benign lymphoepithelial
cyst (cystic BLL) 309–11
chronic sclerosing
sialadenitis 308–9
granulomatous sialadenitis
309
MILAN III 312–13
sialadenosis 305–6
sialolithiasis 306–7
Sjogren's disease 311–12
- oncocyctic carcinoma,
oncocytoma vs. 319
- oncocyctic cystadenoma 326
- oncocytoma 319–20
MASC vs. 325
oncocytosis vs. 319
Warthin's tumor vs. 320
- papillary cystadenocarcinoma
epithelial-myoepithelial
carcinoma vs. 328
polymorphous
adenocarcinoma vs. 327
- pleomorphic adenoma 313–16
adenoid cystic carcinoma
vs. 315
basal cell adenoma vs. 315
cellular 314
MASC vs. 325
mucoepidermoid
carcinoma vs. 316
myoepithelioma vs. 318
oncocytoma vs. 316
polymorphous
adenocarcinoma vs.
315–16
squamous cell carcinoma
vs. 329
with squamous metaplasia
322
- polymorphous
adenocarcinoma 326–7
adenoid cystic carcinoma
vs. 327
epithelial myoepithelial
carcinoma vs. 327
pleomorphic adenoma vs.
315–16
secondary malignancies 332–3
secretory carcinoma 325–6
- sialadenitis
acute 307–8
chronic 312, 329
chronic sclerosing 308–9
chronic sialadenitis with
squamous metaplasia 322
- granulomatous 309
post-irradiation 329
squamous cell carcinoma
vs. 329
- sialadenosis 305–6
acinic cell carcinoma vs.
325
sialolithiasis 306–7
- Sjogren's disease 311–12
- small cell carcinoma
adenoid cystic carcinoma
vs. 323
basal cell adenoma vs. 315
- squamous cell carcinoma
328–9, 332
mucoepidermoid
carcinoma vs. 330
Warthin's tumor vs. 320
- Warthin's tumor 320–1
acinic cell carcinoma vs.
325
benign lymphoepithelial
cyst vs. 321
MASC vs. 325
oncocytoma vs. 320
squamous cell carcinoma
vs. 320
- SALL4 445, 451, 452, 453
- sarcoidosis 52–3, 397, 423
granulomatous (de Quervain's)
thyroiditis vs. 257
- sarcoma
alveolar soft part 513–14
body cavity fluids 112
breast 376–7
fibromatosis vs. 373
metaplastic carcinoma vs.
368
clear cell
kidney 582–3
soft tissues 515–16
clear cell, kidney 582–3
clear cell sarcoma of soft
tissues 515–16
epithelioid 514–15
clear cell carcinoma vs. 516
extrarenal rhabdoid tumor
vs. 517
Ewing's 534–5
granulocytic 412
high-grade 24
histiocytic 412
Kaposi's, hemangioma vs. 541
liver 476–8
angiosarcoma 476–7
embryonal sarcoma 476
epithelioid
hemangioendothelioma
477–8
metastasis 481
lung 437–8
malignant mesenchymal
tumors 376–7
metastatic 225, 242, 271, 438,
481
nodular fasciitis vs. 297
pleomorphic, osteosarcoma
vs. 540
spindle cell (*see* spindle cell
sarcoma)
- synovial 511–12
small round cell tumors
vs. 581
of unknown origin 622
- uterine 24
see also angiosarcoma
sarcomatoid hepatocellular
carcinoma 473
- sarcomatoid malignant
mesothelioma 441
solitary fibrous tumor vs. 441
- sarcomatoid renal cell carcinoma
554, 564–6
adrenocortical carcinoma vs.
566
angiomyolipoma vs. 565–6
leiomyoma vs. 554, 566
renal pelvis urothelial
carcinoma vs. 566
renal sarcoma vs. 554
urothelial carcinoma vs. 564
- Schistosoma haematobium*
in Pap smear 9–10
urinary tract infection 169
- schwannoma
breast, myofibroblastoma vs.
375
GIST vs. 148
head and neck lesions 297–8
mediastinum 453–4
MPNST vs. 455, 527
nodular fasciitis vs. 297
soft tissue and bone 525–6
fibromatosis vs. 522, 525
solitary fibrous tumor vs. 525
- sclerosing adenosis of breast 352
- sclerosing papillary carcinoma 269
- sclerosing sialadenitis 308–9
- secondary malignancies
bladder neoplasms 175
parathyroid gland 285
salivary glands 332–3
- secretory carcinoma, salivary
glands 325–6
- seminoma (dysgerminoma) 112,
450, 606, 612–13
gonadal
embryonal carcinoma vs. 613
spermatocoele vs. 610
spermatocytic 613–14
mediastinal 451–2
Hodgkin's lymphoma vs.
452
metastatic, mediastinal
seminoma vs. 451
thymoma vs. 451
- serous carcinoma from either
ovary or fallopian tube
24–5
- serous cystadenoma 489–91
- Sertoli cell tumor 612
- sialadenitis
acute 307–8
chronic 312, 329
mucoepidermoid
carcinoma vs. 322
sclerosing 308–9
squamous cell carcinoma
vs. 329
squamous metaplasia 322

Index

- sialadenitis (*cont.*)
 granulomatous 309
 lymphoepithelial 311–12
 myoepithelial 311–12
 post-irradiation, squamous cell carcinoma *vs.* 329
- sialadenosis 305–6
 acinic cell carcinoma *vs.* 325
- sialolithiasis 306–9
- sialosis 305–6
- signet ring adenocarcinoma 108
- signet ring carcinoma
 breast, collagenous spherulosis *vs.* 351
 pancreas 494
- “signet-ring” cells 26
- silicone-associated lymphadenitis 402
- silicone granuloma 348
 fat necrosis *vs.* 348
- silicone-related changes, inflammatory breast lesions 348–9
- simple cyst
 kidney 550–2
 liver 464
- Sjogren’s disease 311–12
 benign lymphoepithelial cyst *vs.* 311
- SM-31 214
- SMAD4 494
- small bone metastases 639–40
- small cell carcinoma (SCC)
 bladder 175
 body cavity fluids 102–3
 duodenum 148
 esophagus 133–4
 gastric
 carcinoma *vs.* 144
 lymphoma *vs.* 148
 herpetic esophagitis *vs.* 125
 kidney, small round cell tumors *vs.* 578
 liver 479
 lung 432–3
 carcinoid *vs.* 433
 mediastinal
 B-cell lymphoma *vs.* 445
 precursor T lymphoblastic lymphomas *vs.* 444
 Merkel cell carcinoma *vs.* 293
 metastatic 102–3, 293, 479, 498
 neuroendocrine carcinoma *vs.* 498
 neuroendocrine tumors 71–2
 poorly differentiated 20–1
 well differentiated 479
 poorly differentiated neuroendocrine carcinoma 20–1
- salivary gland
 adenoid cystic carcinoma *vs.* 323
 basal cell adenoma *vs.* 315
 thyroid gland, lymphoma *vs.* 274
- small cell glioblastoma
 multiforme (GBM) 224
- small cell lymphomas 405–8
 follicular 407–8
 mantle cell 405–7
 marginal zone 407
 small lymphocytic lymphoma/
 chronic lymphocytic leukemia 405
- small round blue cell tumors 231–6
 adrenal glands, cortical
 adenoma/hyperplasia *vs.* 584
 central neurocytoma 235–6
 of kidney 578–81
 lymphoma/leukemia 231–4
 oligodendroglioma 234
- smooth muscle actin 315, 373, 377, 419, 437, 454, 477
- smooth muscle tumor, solitary fibrous tumor *vs.* 442
- soft tissue and bone 506–42
 alveolar soft part sarcoma 513–14
 extrarenal rhabdoid tumor *vs.* 516
 granular cell tumor 513
 angiosarcoma 541–2
 chondroblastoma 532–3
 chondroma 539
 chondrosarcoma 537–9
 chordoma 539
 clear cell sarcoma of soft tissues 515–16
 dermatofibrosarcoma protuberans 523–4
 elastofibroma 520–1
 enchondroma 537
 epithelioid sarcoma 514–15
 clear cell carcinoma *vs.* 516
 extrarenal rhabdoid tumor *vs.* 516
 Ewing’s sarcoma 534–5
 extrarenal rhabdoid tumor 516–17
 clear cell carcinoma *vs.* 516
 epithelioid sarcoma *vs.* 516
 fat necrosis 510
 fibromatosis 521–2
 dermatofibrosarcoma protuberans *vs.* 524
 fibrosarcoma *vs.* 525
 leiomyosarcoma *vs.* 528
 myositis ossificans *vs.* 520
 peripheral nerve sheath tumor *vs.* 527
 pseudosarcomatous spindle cell lesions *vs.* 519
 schwannoma *vs.* 526
 solitary fibrous tumor *vs.* 523
 fibrosarcoma 524–5
 fibrous histiocytoma malignant 529–30
 myxoid malignant 510
 giant cell fibroblastoma 523–4
- giant cell tumor of bone,
 conventional 531–2
- granular cell tumor 512–13
 hemangioma 540–1
 intramuscular myxoma 533–4
 Langerhans’ cell histiocytosis 517–18
- leiomyosarcoma 527–8
- lipoma 506–8
 intramuscular 507
 intramuscular lipoma 507
 liposarcoma *vs.* 510
 myelolipoma 508
 pleomorphic 508
 pleomorphic lipoma 508
 spindle cell 507–8
 spindle cell lipoma 507–8
- liposarcoma 508–11
 dedifferentiated 510, 511
 dedifferentiated liposarcoma 510, 511
 high-grade myxoid (round cell) 509
 high-grade myxoid liposarcoma 509
 myxoid 509, 510
 myxoid liposarcoma 509, 510
 pleomorphic 509–10
 pleomorphic liposarcoma 509–10
 well-differentiated 510
 well-differentiated liposarcoma 510
- malignant fibrous histiocytoma 529–30
 dermatofibrosarcoma protuberans 523–4
 giant cell type 531
 melanoma 515, 518
 metastatic malignant 516
 metastatic tumors 515
 large bones 636
 small bones 639
- MPNST 526–7
 myelolipoma 508
 myositis ossificans 519–20
 myxoid chondrosarcoma 510
 myxoma 510, 519
 intramuscular 533–4
 nodular fasciitis 518–19, 520, 522
 osteomyelitis 518
 osteosarcoma 539–40
 pleomorphic
 rhabdomyosarcoma 528–9
 primitive neuroectodermal tumor 534–5
 proliferative fasciitis 518–19, 520
 proliferative myositis 518–19, 520
 pseudosarcomatous proliferations 526
 pseudosarcomatous spindle cell lesions 518–19
- rhabdomyoma 513, 514
 alveolar soft part sarcoma *vs.* 514
 granular cell tumor *vs.* 513
- rhabdomyosarcoma 513, 535–7
 alveolar 513–14, 536
 embryonal 535–6
 granular cell tumor *vs.* 514
 pleomorphic 528–9
- sarcoma
 clear cell 515–16
 Ewing’s 534–5
 spindle cell 518–19
 synovial 511–12
 schwannoma 525–6
 fibromatosis *vs.* 526
 solitary fibrous tumor 522–3
 synovial sarcoma 511–12
 clear cell sarcoma *vs.* 516
 epithelioid sarcoma *vs.* 516
 tenosynovial giant cell tumor 530–1
- solid pseudopapillary neoplasm, pancreas 494–5
- solid thyroid carcinoma 272–3
- solitary fibrous tumor 522–3
 benign peripheral nerve sheath tumor *vs.* 454
 dermatofibrosarcoma protuberans *vs.* 524
 mediastinum 454
 peripheral nerve sheath tumor *vs.* 526
 pleura 441–2
 schwannoma *vs.* 525
 soft tissue and bone 522–3
 dermatofibrosarcoma protuberans *vs.* 524
 fibromatosis *vs.* 523
 fibrosarcoma *vs.* 525
 leiomyosarcoma *vs.* 528
- specimen types in breast
 cytopathology 340–2
 ductal lavage 341–2
 fine needle aspiration biopsy of the breast 340–1
 nipple discharge cytology 342
 spermatocele 609–10
 spermatocytic seminoma 613–14
- spindle cell
 cytomorphologic/architectural patterns 629–30
 metastases in bone, clinical patterns of 636
 pseudosarcomatous 518–19
 spindle cell lipoma breast 374
 schwannoma *vs.* 298
 soft tissue and bone 507–8
 liposarcoma *vs.* 510
 spindle cell melanoma 455
 spindle cell sarcoma 298, 440
 mediastinum 455
 pleura, mesothelioma *vs.* 440
 schwannoma *vs.* 298
 soft tissue and bone

- fibromatosis *vs.* 522
 myositis ossificans *vs.* 520
 pseudosarcomatous spindle cell lesions *vs.* 519
 spindle cell thymoma, benign
 peripheral nerve sheath tumor *vs.* 454
 spindle cell tumors
 bone 507–8, 510, 636
 breast, myofibroblastoma *vs.* 375
 of unknown origin 629–30
 spleen metastases 640
 sputum 37–8
 squamous cell carcinoma (SQCC)
 benign lymphoepithelial cyst *vs.* 310
 bladder neoplasms 174
 body cavity fluids 101–2
 breast 368
 cervix
 keratinizing 18–19
 non-keratinizing 19
 papillary 19–20
 cystic 288–9
 esophagus 130–1
 radiation/chemotherapy-related esophagitis *vs.* 127
 small cell carcinoma *vs.* 131
 exfoliative pulmonary cytology 63–5
 herpetic esophagitis *vs.* 125
 keratinizing 18–19
 liver 480–1
 lung 428–30
 basaloid 433
 large cell undifferentiated carcinoma *vs.* 430
 mucoepidermoid carcinoma *vs.* 435
 nonkeratinizing 19
 pilomatrixoma *vs.* 295
 renal pelvis, renal metastatic carcinoma *vs.* 569
 respiratory system 63–5
 salivary gland 328–9, 332
 mucoepidermoid carcinoma *vs.* 322
 Warthin's tumor *vs.* 320
 of unknown origin 621
 squamous (SQ) cells 38–9
 squamous dysplasia, anal 152–4
 squamous intraepithelial lesion (SIL) 3
 steatosis 467–8
 stereotactic needle biopsy technique 202
 stomach 135–44
 adenocarcinoma 138–40
 chemotherapy-associated atypia 138
 dysplasia 137–8
 gastric dysplasia 137–8
 polyps *vs.* 138
 gastric polyps 138
 gastritis 135–6
 GIST 142–3
 lymphoma 143–4
 neuroendocrine tumor 140–2
 peptic ulcer disease 136–7
 polyps 138
 tumors (*see* gastric tumors)
 stromal tumors 611–12
 Leydig cell tumor 611–12
 Sertoli cell tumor 612
 subacute cerebral infarction 214
 subacute sclerosing panencephalitis 210
 subacute thyroiditis 257–8
 subareolar abscess 346–7
 breast cyst *vs.* 350
 inflammatory breast lesions 346–7
 metaplastic carcinoma *vs.* 368
 squamous cell carcinoma *vs.* 368
 SV-40 210
 synaptophysin 20, 102, 197, 235, 236, 238, 240, 241, 252, 271, 293, 294, 379, 419, 479, 496, 497, 535, 584, 585, 587, 589
 synovial sarcoma 441, 511–12
 small round cell tumors *vs.* 581
 soft tissue and bone 511–12
 clear cell sarcoma *vs.* 516
 epithelioid sarcoma *vs.* 516
 solitary fibrous tumor *vs.* 441
 systemic lupus erythematosus (SLE), effusions 88–9
 T-cell lymphoma
 lymph nodes 409–10
 mediastinum 448–9
 peripheral 410
 T-cell rich B-cell lymphoma 404
 Hodgkin's lymphoma *vs.* 450
 “tadpole cells” 18
 tall cell papillary thyroid carcinoma 269
 TdT 415, 448
 tenosynovial giant cell tumor 530–1
 giant cell tumor of bone *vs.* 531
 pleomorphic malignant fibrous histiocytoma *vs.* 531
 teratoma 615–16
 gonadal 615–16
 mediastinal 450–1
 terminal deoxynucleotidyl transferase *see* TdT
 testicular tumors 609–11
 adenomatoid tumor 610–11
 choriocarcinoma 615
 embryonal carcinoma 614
 epididymitis/orchitis 610
 hemocele 610
 hydrocele 609
 Leydig cell tumor 611–12
 lymphoma 611
 Sertoli cell tumor 612
 spermatocele 609–10
 spermatocytic seminoma 613–14
 teratoma 615–16
 yolk sac tumor 614–15
 thecoma 608
 thiotepa 170
 thrombomodulin 95, 557, 566
 thymic carcinoid, thymic carcinoma *vs.* 446
 thymic carcinoma 445–6
 metastatic 445
 thymic carcinoid *vs.* 446
 thymic cysts 443
 thymic germ cell tumor, thymic carcinoma *vs.* 445
 thymic hyperplasia, thymoma *vs.* 444
 thymic lymphocytes 444, 448, 454
 thymic neuroendocrine tumor 446–7
 metastatic 446
 thymoma 433–45
 cystic 444
 Hodgkin's lymphoma *vs.* 445
 mediastinal B-cell lymphoma *vs.* 448
 mediastinal seminoma *vs.* 451
 precursor T-cell lymphoblastic lymphoma *vs.* 444
 spindle cell 454
 type A 444
 type AB 444
 type B 444
 thyroglobulin 634
 thyroglossal duct cyst 287–8
 thyroid follicular nodule *vs.* 253
 thyroid gland 251–75
 adequacy of biopsy 252
 atypia of undetermined significance 260–2
 molecular testing 261
 benign follicular nodules 252–9
 acute thyroiditis 256–7
 adenomatoid (hyperplastic) nodule 252–5
 amyloid goiter 259
 chronic lymphocytic (Hashimoto's) thyroiditis 255–6
 colloid nodule 252–5
 follicular nodule 252–5
 granulomatous thyroiditis 257–8
 granulomatous (de Quervain's) thyroiditis 257–8
 Graves' disease 258–9
 Riedel's thyroiditis 258
 colloid nodule 252–5
 follicular nodule 252–5
 granulomatous thyroiditis 257–8
 granulomatous (de Quervain's) thyroiditis 257–8
 Graves' disease 258–9
 Riedel's thyroiditis 258
 Bethesda System 251–2
 follicular lesion of undetermined significance 260–2
 introduction 251–2
 adequacy, statement on 252
 Bethesda System 251–2
 lymphoma 274–5
 Hashimoto's thyroiditis *vs.* 274
 poorly differentiated thyroid carcinoma *vs.* 273
 malignant nodules 267–75
 anaplastic carcinoma 273–4
 cystic papillary carcinoma 289–90
 lymphoma 274–5
 medullary thyroid carcinoma 270–2
 metastatic tumors 275
 papillary thyroid carcinoma 267–70
 poorly differentiated thyroid carcinoma 272–3
 suspicious for malignancy 265–7
 undifferentiated (anaplastic) thyroid carcinoma 273–4
 metastatic tumors 275, 638
 neoplasm 262–5
 follicular neoplasm 262–3
 NIFTP 262–3
 oncocyctic (Hürthle cell) neoplasms 263–5
 thyroid transcription factor 1 *see* TTF-1
 thyroiditis
 acute 256–7
 chronic lymphocytic (Hashimoto's) 255–6
 granulomatous (de Quervain's) thyroiditis *vs.* 257
 Graves' disease *vs.* 259
 Hürthle cell neoplasm *vs.* 256
 lymphoma *vs.* 256
 Riedel's thyroiditis *vs.* 258
 granulomatous (subacute or de Quervain's) 257–8
 acute thyroiditis *vs.* 257
 Riedel's thyroiditis *vs.* 258
 Riedel's 258
 toxocara 192–3
 toxocariasis, intraocular cytology 192
 toxoplasmosis
 central nervous system 211–13
 intraocular cytology 192
 trabecular adenoma 316–18
 trabecular thyroid carcinoma 272–3

Index

- tracheobronchial lining cells
 39–40
 reactive/repairative changes
 40–1
- transudates 83
- trichomes, in Pap smear 12–13
Trichomonas vaginalis, in Pap
 smear 8
- TTF-1 98–109, 111, 133, 317,
 380, 381, 418, 428, 430,
 433, 435, 437–9, 443,
 446, 479, 499, 561
- tubal metaplasia 5
- tuberculous effusions 89
- tuberculous lymphadenitis 396
 acute lymphadenitis *vs.* 396
- tubular adenoma 316–18, 352–3
- tubular carcinoma 363–5
- tumor markers 620
see also specific markers
- tumor-to-tumor metastasis 640
- tumors of unknown origin
*see malignancies of
 unknown primary site
 (MUP)*
- typical carcinoid 69–71
- undifferentiated pleomorphic
 sarcoma 529–30
 myxoid malignant 510
- undifferentiated (anaplastic)
 thyroid carcinoma
 (UTC) 273–4
- uremia, effusions 91
- urinary bladder washing 166
- urinary cytology 160–78
 bladder neoplasms, other
 174–5
 adenocarcinoma 174–5
 secondary malignancies
 175
 small cell carcinoma 175
 squamous cell carcinoma
 174
- inflammatory conditions
 166–9
- noninfectious 166
- other infectious agents
 167–9
- polyoma virus 166–7
- normal urine, elements of
 162–5
- Paris System 160–2
 diagnostic categories and
 criteria 160–2
 introduction 160
- treatment-related changes 170
 Bacillus Calmette–Guerin
 granulomas 170
 cyclophosphamide 170
 mitomycin and thiotepa
 170
 radiation 170, 171
- urine specimens 165–6
 catheterized urine 165
 ileal conduit 166
 urinary bladder washing
 166
 voided urine 165
- uroolithiasis 169
- urothelial carcinoma 170–4
 fine-needle aspiration of
 175–8
 high-grade urothelial
 carcinoma 171–4
 low-grade urothelial
 carcinoma 170
- urine
 normal, elements of 162–5
 specimens 165–6
 catheterized urine 165
 ileal conduit 166
 urinary bladder washing
 166
 voided urine 165
- uroolithiasis 169, 172
- uropelakins 27, 28
- urothelial cell carcinoma (UCC)
 170–4
 body cavity fluids 115–16
 clear cell renal cell carcinoma
vs. 557
- collecting duct renal cell
 carcinoma *vs.* 564
- cytology 169
- fine-needle aspiration of
 175–8
- high-grade 171–4
- low-grade 170
- metastatic, Brenner tumor
vs. 603
- on Pap smear 27
- papillary renal cell carcinoma
vs. 557
- renal metastatic carcinoma
vs. 569
- renal pelvis 566–7
- sarcomatoid renal cell
 carcinoma *vs.* 564
- uterine carcinoma, of Mullerian
 origin 105
- uterine sarcoma 24
- uveitis, idiopathic chronic 193
- vacuolated histiocytes 46
- Veracyte's *Afirma* analysis 261
- villin 108, 634
- villous adenoma, gastric
 adenocarcinoma *vs.* 146
- vimentin 275, 296, 372–3,
 375–7, 419, 445, 468–9,
 476–7, 494, 507, 510–12,
 515–17, 523, 528, 530,
 535, 536, 554–7, 559,
 562, 564–6, 571, 578,
 582, 606–9, 612, 613
- viral endophthalmitis 191–2
- viral infections
 central nervous system
 208–11
 cytomegalovirus 211
 herpes virus 210–11
 Mollaret meningitis 211
 progressive multifocal
 leukoencephalopathy
 209–10
 subacute sclerosing
 panencephalitis 210
- viral meningitis 208–9
 effusions 89–90
 respiratory 59–60
see also specific viral infections
- viral meningitis 181, 208–9
- voided urine specimens 165
- vulva, Paget's disease 27–8
- Warthin's tumor 320–1
 acinic cell carcinoma *vs.* 320
 benign lymphoepithelial cyst
vs. 321
 MASC *vs.* 326
 mucoepidermoid carcinoma
vs. 320
 oncocytoma *vs.* 320
 squamous cell carcinoma *vs.*
 329
- Wegener's granulomatosis 424
 lung abscess *vs.* 423
- well-differentiated liposarcoma
 510
- well differentiated NET and
 small cell carcinoma
 (neuroendocrine tumor)
 479
- Wilms tumor *see*
 nephroblastoma
- Wilms' tumor 1 protein *see*
 WT-1
- World Health Organization
 (WHO) classification
 updates 202–3
- WT-1 94, 98–107, 116, 558, 578,
 580, 601–2, 634
- X-linked inhibitor of apoptosis
 protein *see* XIAP
- xanthogranulomatous
 pyelonephritis (XGP)
 574–5
- XIAP 95
- yolk sac tumor 614–15
- zygomycetes 58